Biomimetic peptide serum with self-assembling amphiphilic peptides for management of skin after a cosmetic procedure
Patent Information
- Application Number
- PCT/US2026/028263
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Existing aftercare treatments for cosmetic procedures like laser resurfacing fail to provide a multifaceted approach for accelerated tissue repair, skin hydration, inflammation modulation, and protection against bacterial colonization, leading to prolonged recovery and potential infection.
A method involving the topical administration of a purified amphiphilic peptide solution that self-assembles into a hydrogel, comprising charged and hydrophobic amino acid residues in an alternating pattern, to accelerate healing, reduce inflammation, and prevent infection.
The peptide hydrogel significantly reduces recovery time, inflammation, and infection risk, achieving at least 75% re-epithelization within 14 days, 10% inflammation reduction within 48 hours, and 50% redness reduction within 48 hours, with the potential to shorten recovery to less than 7 days.
Smart Images

Figure US2026028263_19112026_PF_FP_ABST
Abstract
Description
[0001] Docket No. G2093-7013WO
[0002] BIOMIMETIC PEPTIDE SERUM WITH SELF-ASSEMBLING AMPHIPHILIC PEPTIDES FOR MANAGEMENT OF SKIN AFTER A COSMETIC PROCEDURE
[0003] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application Serial No. 63 / 805,514 titled “BIOMIMETIC PEPTIDE SERUM WITH SELF- ASSEMBLING AMPHIPHILIC PEPTIDES FOR MANAGEMENT OF SKIN AFTER A COSMETIC PROCEDURE” filed May 14, 2025, which is herein incorporated by reference in its entirety for all purposes.
[0004] SEQUENCE LISTING
[0005] The instant application contains a Sequence Listing which has been submitted electronically in XML (extensible Markup Language) and is hereby incorporated by reference in its entirety. Said XML copy, created on April 13, 2026, is named G2093-7013WO_SL.xml.
[0006] HELD OF TECHNOLOGY
[0007] Aspects and embodiments disclosed herein are directed toward topical administration of selfassembling peptide hydrogel formulations. In particular, aspects and embodiments are directed toward self-assembling amphiphilic peptide formulations and methods for the management of skin after cosmetic procedures.
[0008] BACKGROUND
[0009] Skin injuries caused by cosmetic procedures, such as microneedling and resurfacing laser skin treatments, carry risks related to healing and regeneration such as prolonged recovery, inflammation, and potential for infection. Existing aftercare treatments fail to provide a multifaceted approach to recovery, including accelerated tissue repair, skin hydration, inflammation modulation, and protection against bacterial colonization.
[0010] Resurfacing laser skin treatments have emerged as a highly effective solution for addressing a variety of skin concerns, including wrinkles, acne scars, pigmentation issues, and sun damage. Laser skin treatments can stimulate collagen production, remove damaged skin layers, and promote the regeneration of healthier skin cells. As technological advancements have refined laser therapy options, patients now have access to a variety of laser resurfacing skin treatments, each offeringDocket No. G2093-7013WO
[0011] unique benefits in terms of results, downtime, and patient suitability. Laser skin procedures are able to provide safer and more efficient ways to achieve smoother, more youthful skin.
[0012] Following a laser resurfacing treatment, the skin typically enters a recovery phase characterized by redness, swelling, and the potential for peeling or crust formation as it heals and regenerates. Typical care instructions include avoiding direct sunlight, keeping the skin clean to prevent infection, applying ointments or moisturizers to keep the skin hydrated, and using cold compresses to reduce swelling. Even following the typical aftercare instructions, the immediate side effects can last up to 7 days or more. There is a need for materials that protect and heal the skin immediately after a laser resurfacing treatment, to reduce or shorten the post-treatment recovery phase.
[0013] Tissue engineering involves the use of materials with suitable biochemical and physiological properties to replace, repair, and / or enhance biological tissues. The particular tissue involved may have certain mechanical and structural requirements for proper functioning. There is a need for materials which are easily tunable for use with a particular target tissue and have suitable biochemical and physiological properties for tissue engineering.
[0014] Peptides, due to their inherent biocompatibility, tunable functionality, and versatility, are emerging as promising candidates for addressing these challenges. However, current peptide formulations are limited in their ability to combine antimicrobial, anti-inflammatory, and skinpenetrating properties with customizable structural and functional benefits.
[0015] SUMMARY
[0016] In accordance with one aspect, there is provided a method of reducing length of a recovery phase or accelerating healing and / or regeneration of skin after a cosmetic procedure. The method may comprise administering the cosmetic procedure to target skin of a subject. The method may comprise administering to the target skin a preparation comprising a purified amphiphilic peptide in an aqueous biocompatible solution, the peptide comprising a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern, the peptide being configured to self-assemble into a hydrogel.
[0017] In accordance with another aspect, there is provided a method of treating or preventing a symptom or side effect of a cosmetic procedure. The method may comprise administering the cosmetic procedure to target skin of a subject. The method may comprise administering to the target skin a preparation comprising a purified amphiphilic peptide in an aqueous biocompatible solution, the peptide comprising a folding group having a plurality of charged amino acid residues andDocket No. G2093-7013WO
[0018] hydrophobic amino acid residues arranged in a substantially alternating pattern, the peptide being configured to self-assemble into a hydrogel.
[0019] In some embodiments, the cosmetic procedure comprises a laser resurfacing or dermabrasion procedure, microneedling or dermarolling, chemical peel, radiofrequency (RF) skin tightening, laser treatment, application of an injectable, such as a neurotoxin or filler, cryotherapy, thread lift, such as a non-surgical face lift, microblading, tattooing or permanent makeup, laser hair removal or intense pulsed light (IPL), a tattoo removal procedure, platelet rich plasma (PRP) injection, or a surgical cosmetic procedure.
[0020] In some embodiments, the surgical cosmetic procedure comprises a skin tightening procedure, a fat reduction procedure, or a hair transplant procedure.
[0021] In some embodiments, accelerating healing and / or regeneration of skin comprises at least one of: accelerating re-epithelization by at least 75% within 14 days of administration; reducing inflammation and / or irritation by at least 10% within 48 hours from administration; reducing redness by at least 50% within 48 hours from administration; and restoring at least 25% of normal skin barrier function as measured by transepidermal water loss within 48 hours from administration.
[0022] In some embodiments, the symptom or side effect is redness, swelling, peeling, cmst formation, itching, burning, scarring, erythema, contact dermatitis, milia, pain, discomfort, or a combination thereof.
[0023] In some embodiments, the symptom or side effect is a microbial infection.
[0024] In some embodiments, the length of the recovery phase is reduced to less than 7 days, e.g., less than 6 days, less than 5 days, less than 4 days, less than 3 days, less than 2 days, or less than 1 day.
[0025] In some embodiments, the target skin is an integumental tissue selected from an epidermal, dermal, or hypodermal tissue.
[0026] In some embodiments, the target skin is on one or more of the face, forehead, eye region, cheek, nose, neck, scalp, head, shoulder, arm, hands, leg, underann, torso, chest, feet, knee, ankle, calf, thigh, or buttocks of the subject.
[0027] In some embodiments, the preparation is administered less than 1 hour, e.g., less than 30 minutes, less than 25 minutes, less than 20 minutes, less than 15 minutes, less than 10 minutes, or less than 5 minutes after the cosmetic procedure.
[0028] In some embodiments, a second or booster dose of the preparation is administered at least 6 hours, e.g., at least 12 hours, at least 24 hours, at least 48 hours, or at least 72 hours after an initial administration of the preparation.Docket No. G2093-7013WO
[0029] In some embodiments, the preparation is administered topically.
[0030] In some embodiments, the preparation is formulated for topical administration to the target skin.
[0031] In some embodiments, the preparation is formulated as an aqueous solution, gel, lotion, ointment, cream, serum, oil, salve, and / or solid, e.g., powder.
[0032] In some embodiments, the preparation is formulated for administration by spray, aerosol, dropper, tube, ampule, or syringe.
[0033] In some embodiments, the preparation is formulated as a film, membrane, sheet, barrier dressing, or impregnated material, e.g., mask or bandage.
[0034] In some embodiments, the preparation is formulated for parenteral administration to the target skin.
[0035] In some embodiments, the preparation consists of or consists essentially of the purified amphiphilic peptide in the aqueous biocompatible solution.
[0036] In some embodiments, the method further comprises administering to the target skin a buffer configured to induce self-assembly of the peptide into the hydrogel.
[0037] In some embodiments, the method comprises combining the preparation and the buffer prior to administration, e.g., less than about 1 minute, less than about 2 minutes, less than about 5 minutes, or less than about 10 minutes prior to administration.
[0038] In some embodiments, the preparation and the buffer are administered separately.
[0039] In some embodiments, the buffer comprises an effective amount of an ionic salt and a biological buffering agent.
[0040] In some embodiments, the buffer comprises between about 10 mM and 150 mM sodium chloride and between about 10 mM and 100 mM Bis-tris propane (BTP).
[0041] In some embodiments, the folding group comprises a turn sequence having 2-8 turn sequence amino acid residues selected to adopt a 0-turn.
[0042] In some embodiments, the turn sequence amino acid residues are independently selected from a D-proline, an L-proline, aspartic acid, threonine, asparagine, and combinations thereof.
[0043] In some embodiments, the turn sequence amino acid residues comprise a D-proline.
[0044] In some embodiments, the folding group comprises a first arm and a second ami flanking the turn sequence, each arm comprising alternating hydrophobic amino acid residues and charged amino acid residues.
[0045] In some embodiments, the folding group comprises 16-24 amino acid residues.Docket No. G2093-7013WO
[0046] In some embodiments, the hydrophobic amino acid residues are independently selected from glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, threonine, tryptophan, and combinations thereof. In some embodiments, the charged amino acid residues are independently selected from arginine, lysine, histidine, and combinations thereof.
[0047] In some embodiments, the folding group has a sequence comprising Y[XY]N[T][XY]M, where X is 1-3 charged amino acids, Y is 1-3 hydrophobic amino acids, T is 0-8 turn sequence amino acids, and N and M are each independently between 2 and 10.
[0048] In some embodiments. X is selected from lysine and arginine, Y is valine, T is (d)PPT, and N and M are each 4.
[0049] In some embodiments, the peptide has a sequence of SEQ ID NO: 2.
[0050] In some embodiments, the peptide has a sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 99, and SEQ ID NO: 100.
[0051] In some embodiments, the peptide is at least 80% purified, for example, at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or at least 99.9%.
[0052] In some embodiments, the preparation is substantially free of a preservative.
[0053] In some embodiments, the preparation comprises between 0.01% w / v and 8.0% w / v of the peptide.
[0054] In some embodiments, the preparation comprises between 0.1% w / v and 8.0% w / v of the peptide, for example, between 0.1% w / v and 2.5% w / v, between 0.5% w / v and 6.0% w / v of the peptide, between 0.5% w / v and 3.0% w / v of the peptide, between 0.5% w / v and 1.5% w / v of the peptide, between 0.5% w / v and 1.0% w / v of the peptide, or between 0.7% w / v and 0.8% w / v of the peptide.
[0055] In some embodiments, the hydrogel comprises between 0.25% w / v and 6.0% w / v of the peptide. In some embodiments, the hydrogel comprises between 0.1% w / v and 2.5% w / v of the peptide.
[0056] In some embodiments, the peptide has a net charge of from -10 to +11.
[0057] In some embodiments, the peptide has a net charge of from +2 to +9, e.g., from +5 to +9 at pH 7.4.
[0058] In some embodiments, the preparation and / or the hydrogel is sterilized.
[0059] In some embodiments, the preparation is administered in combination with an antiinflammatory agent, an ointment or moisturizer, a UV blocker, cold compress, analgesic or painrelief composition, antibacterial composition, antifungal composition, antiviral composition, cellDocket No. G2093-7013WO
[0060] culture media, cell culture serum, a hemostatic composition, a biological material, or a combination thereof.
[0061] In some embodiments, the peptide comprises acetate or citrate counterions.
[0062] In some embodiments, the peptide comprises acetate counterions.
[0063] In some embodiments, the peptide is free of chloride counterions.
[0064] In some embodiments, the peptide has a free amine at the N-terminus.
[0065] In accordance with another aspect, there is provided a method of facilitating regeneration of skin after a cosmetic procedure. The method may comprise providing a preparation comprising a purified amphiphilic peptide comprising a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern, the peptide being configured to self-assemble into a hydrogel. The method may comprise providing instractions to administer an effective amount of the preparation to a target skin of a subject that has received the cosmetic procedure.
[0066] In some embodiments, the method may further comprise providing a buffer configured to induce self-assembly of the peptide into the hydrogel.
[0067] In some embodiments, the preparation and the buffer are combined to form the hydrogel, and the method comprises providing instructions to administer an effective amount of the hydrogel to the target skin.
[0068] In some embodiments, the method may further comprise providing instructions to combine the preparation and a buffer configured to induce self-assembly of the peptide into the hydrogel prior to administration.
[0069] In accordance with another aspect, there is provided a preparation comprising a purified amphiphilic peptide comprising a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern, the peptide being configured to self-assemble into a hydrogel, the preparation being formulated as a lotion, ointment, cream, serum, oil, or salve for topical application to skin.
[0070] In accordance with another aspect, there is provided a preparation comprising a purified amphiphilic peptide comprising a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern, the peptide being configured to self-assemble into a hydrogel, the preparation being formulated as an impregnated material for topical application to skin.Docket No. G2093-7013WO
[0071] In some embodiments, the impregnated material is a mask, e.g., a facial sheet mask, under eye mask or patch, spot patch or spot dot, forehead patch, chin patch, cheek patch,jawline or v-line lifting patch, nose patch or nose strip, neck mask, and / or chest mask.
[0072] In some embodiments, the folding group has a sequence comprising Y[XY]N[T][XY]M, where X is 1-3 charged amino acids, Y is 1-3 hydrophobic amino acids, T is 0-8 turn sequence amino acids, and N and M are each independently between 2 and 10.
[0073] In some embodiments, X is selected from lysine and arginine, Y is valine, T is (d)PPT, and N and M are each 4.
[0074] In some embodiments, the peptide has a sequence of SEQ ID NO: 2.
[0075] In some embodiments, the preparation is substantially free of a preservative.
[0076] In some embodiments, the preparation comprises between 0.01% w / v and 8.0% w / v of the peptide.
[0077] In some embodiments, the preparation comprises between 0.1% w / v and 2.5% w / v of the peptide.
[0078] In some embodiments, the peptide has a net charge of from -10 to +11.
[0079] In some embodiments, the peptide has a net charge of from +5 to +9 at pH 7.4.
[0080] In some embodiments, the peptide comprises acetate counterions.
[0081] In some embodiments, the peptide is free of chloride counterions.
[0082] In some embodiments, the peptide has a free amine at the N-terminus.
[0083] BRIEF DESCRIPTION OF THE DRAWINGS
[0084] The accompanying drawings are not intended to be drawn to scale. In the drawings, each identical or nearly identical component that is illustrated in various figures is represented by a like numeral. For purposes of clarity, not every component may be labeled in every drawing. In the drawings:
[0085] FIG. 1 A includes schematic and microscopic images of an assembled peptide hydrogel matrix with encapsulated cells as compared to collagen, according to one embodiment;
[0086] FIG. IB includes a schematic drawing of a mixing device and a schematic representation of cells in a hydrogel matrix, according to one embodiment;
[0087] FIG. 2 includes images of sustained therapeutic activity of the administered peptide hydrogel compared to conventional polymer, according to one embodiment;
[0088] FIG. 3 is a microscopy image of positively charged peptide hydrogels, according to one embodiment;Docket No. G2093-7013WO
[0089] FIG. 4 is a graph showing the antimicrobial activity of the peptide hydrogel, in accordance with one embodiment;
[0090] FIG. 5 includes images of a mouse model post-burn injury with bacterial infection showing antimicrobial activity of the peptide hydrogel, in accordance with one embodiment;
[0091] FIG. 6 includes microscopy images of cells engrafted on the peptide hydrogels, according to one embodiment;
[0092] FIG. 7A is a graph of static light scattering (SLS) at 266 nm of exemplary peptides as a function of temperature, according to some embodiments;
[0093] FIG. 7B is a graph of static light scattering (SLS) at 266 nm of exemplary peptides as a function of temperature, according to some embodiments;
[0094] FIG. 8 includes graphs showing absorbance of a peptide hydrogel as a function of peptide concentration, according to one embodiment;
[0095] FIG. 9 is a graph showing net charge of a peptide preparation as a function of pH value, according to one embodiment;
[0096] FIG. 10 is a visual representation of net peptide charge at a pH of 7.4 for several amino acid residues, according to one embodiment;
[0097] FIG. 11 is a line drawing of a photograph of the preparation provided in an end-use container, according to one embodiment;
[0098] FIG. 12 is a graph of microbial proliferation of MRS A after treatment with the peptide preparation, according to one embodiment;
[0099] FIG. 13 is a graph of storage modulus and loss modulus of the preparation, according to one embodiment;
[0100] FIG. 14A is a graph showing growth of P. aeruginosa after application of the preparation, according to one embodiment;
[0101] FIG. 14B is a graph showing growth of MRS A after application of the preparation, according to one embodiment;
[0102] FIG. 15A is a graph of storage modulus and loss modulus of the preparation, according to one embodiment;
[0103] FIG. 15B is a graph of storage modulus and loss modulus of the preparation, according to one embodiment;
[0104] FIG. 16 is a graph of antimicrobial activity of the preparation, according to one embodiment; FIG. 17A is a graph of UPLC of the preparation, according to one embodiment;
[0105] FIG. 17B is a graph of UPLC of the preparation, according to one embodiment;Docket No. G2093-7013WO
[0106] FIG. 18 is a graph of antimicrobial activity of the preparation, according to one embodiment; FIG. 19 is a graph of cell viability of the preparation, according to one embodiment; and FIG. 20 is a graph of rheological data of the preparation, according to one embodiment.
[0107] DETAILED DESCRIPTION
[0108] Preparations comprising self-assembling peptide hydrogels are disclosed herein. The selfassembled peptide may be amphiphilic. The peptide may generally have a folding group having a plurality of charged amino acid residues and hydrophobic residues arranged in a substantially alternating pattern. The peptide may include functional groups to provide desired physical or chemical properties upon administration. The purified peptide may include counterions that improve biocompatibility of the preparation. The counterions may control the self-assembly, physical and chemical properties of the peptide. The counterions may enhance the therapeutic functional properties of the peptide. The preparation may include the peptide in an aqueous biocompatible solution. The preparation may include a buffer solution capable of inducing self-assembly of the peptide upon contact. The buffer solution may contain a buffering agent and ionic salts. The buffer solution composition may be designed to control the assembled hydrogel’s physical or chemical properties. The preparation may be designed to be thermally stable.
[0109] In general, the preparation may have shear-thinning properties and a substantially physiological pH level. The self-assembled hydrogel may have antimicrobial, antiviral, and / or antifungal properties. The preparation may be administered topically or parenterally. The preparation may be administered for tissue engineering applications. In certain embodiments, the preparation may be administered for management of post-laser resurfacing or dermabrasion. Other exemplary applications include cell delivery, cell culture, treatment and prevention of fungal infections, treatment and prevention of bacterial infections, wound healing, biofilm treatment, biofilm management, and prevention of biofilm and wound infection, including infection of chronic wounds. Other tissue engineering applications are within the scope of the disclosure.
[0110] Methods of administering the preparation to a subject are disclosed herein. The methods may generally include selecting a target site for administration and administering the preparation to the target site. Methods of administering the preparation may also include mixing the preparation with a buffer configured to induce self-assembly of the peptide to form the hydrogel and administering the hydrogel to the target site. Tn certain exemplary embodiments, the preparation and / or hydrogel may be administered by spray, aerosol, dropper, tube, ampule, instillation, injection, or syringe.Docket No. G2093-7013WO
[0111] In certain embodiments, methods of administering cells to a subject are disclosed herein. The methods may generally include suspending the cells in a solution comprising a self-assembling peptide and administering an effective amount of the suspension to a target site of the subject. The methods may comprise combining the solution with a buffer configured to induce self-assembly of the peptide. The solution may be combined with the buffer prior to administration, concurrently with administration, or after administration. The buffer may generally comprise an effective amount of an ionic salt and a biological buffering agent.
[0112] Unlike other peptides in aqueous solution, the peptides disclosed herein undergo selfassembly. The self-assembly may enable the peptides to be administered in a concentrated or localized manner to a target tissue. For example, self-assembling peptides may be administered at higher concentrations when compared to free floating peptides. The self-assembling peptides may exhibit the clinical benefit of reducing offsite toxicity of the peptides, due to the localizing effect upon administration. Additionally, the therapeutic dosage of peptides may be increased in the vicinity of the target administration site.
[0113] Unlike other polymers in aqueous solution, the peptides disclosed herein may undergo selfassembly in situ at the target site. The in situ self-assembly may enable the peptides to be administered to a target tissue and allow to physically or ionically crosslink, for example, within seconds of administration. For example, self-assembling peptides may be administered directly to target site. Conventional free-floating peptides or polymers usually need a crosslinking agent or exogenous added covalent crosslinking agent. Thus, the self-assembling peptides disclosed herein may provide the clinical benefit of reducing product application and complexity. Additionally, the ionic crosslinking of peptides upon self-assembly may provide the benefit of selecting between product removal and permanent adherence to a target administration site.
[0114] Select Definitions
[0115] Hydrogels are a class of materials that have significant promise for use in soft tissue and bone engineering. The general characteristic of hydrogels that make them important materials for these applications are their well hydrated, porous structure. Hydrogels may be designed to be compatible with the adhesion and proliferation of various cell types, e.g., fibroblasts and osteoblasts, making them potential tissue engineering scaffolds for generating connective tissue, such as cartilage, tendons, and ligaments, and bone.
[0116] The hydrogel material may be cytocompatible. Cytocompatibility, defined herein, means that the hydrogel must not be adverse to desired cells, in vitro and / or in vivo. Adversity to cells may beDocket No. G2093-7013WO
[0117] measured by cytotoxicity, cell adhesion, proliferation, phenotype maintenance, and / or differentiation of progenitor cells.
[0118] The materials described herein may be biocompatible. “Biocompatible,” defined herein, means that a material does not cause a significant immunological and / or inflammatory response if placed in vivo. Biocompatibility may be measured according to International Organization for Standardization (ISO) 10993 standards.
[0119] The hydrogel material may be biodegradable affording non-toxic species. The hydrogel material may be proteolytically biodegradable. “Proteolytic” biodegradation, defined herein, refers to local degradation of the material in response to the presence of cell-derived proteases and / or gradual degradation with the proliferation of cells. The hydrogel material may be hydrolytically biodegradable. “Hydrolytic” biodegradation, defined herein, refers to polymer degradation without assistance from enzyme under biologic conditions.
[0120] The hydrogel material may be bioresorbable. Bioresorbable, defined herein, means that the hydrogel material breaks down into remnants that are natural products readily absorbed into the body, resulting in complete loss of original mass.
[0121] The hydrogel material may be referred to as being shear-thinning. “Shear-thinning,” as described herein, refers to a variable apparent viscosity, in particular, a decreasing viscosity with increasing applied stress. For instance, the shear-thinning hydrogel may exhibit non-Newtonian fluid properties. In particular the hydrogels disclosed herein may be administered through a needle or catheter and rapidly resume gelation after removal of the mechanical force.
[0122] The hydrogel and / or other materials disclosed herein may be referred to as having one or more physiological properties. As disclosed herein, physiological properties or values refer to those which are compatible with the subject. In particular, physiological properties or values may refer to those which are compatible with a particular target tissue. In certain embodiments, physiological properties or values may refer to those which are substantially similar to the properties or values of the target tissue. Physiological properties may include one or more of pH value, temperature, net charge, water content, stiffness, and others.
[0123] “Self-assembling” peptides include such peptides which, typically, after being exposed to a stimulus, will assume a desired secondary structure. The peptides may self-assemble into a higher order structure, for example a three-dimensional network and, consequently, a hydrogel. The selfassembled hydrogel may contain peptides in a tertiary and / or quaternary structure through charge screening, hydrophobic, and disulfide interactions. Peptides have been observed to self-assemble into helical ribbons, nanofibers, nanotubes and vesicles, surface-assembled structures and others. Self-Docket No. G2093-7013WO
[0124] assembling peptides may assemble responsive to certain environmental conditions, e.g., pH, temperature, net charge, exposure to light, applied sound wave, or presence or absence of environmental factors. The environmental conditions may occur upon administration to a subject or by combination with a buffer. In other embodiments, the peptide may assemble spontaneously in solution under neutral pH level. The peptide may assemble spontaneously in solution under physiological conditions and / or in the presence of a cation and / or anion.
[0125] The self-assembling peptides may assemble into an alpha helix, pi-helix, beta sheet, random coil, turn, beta pleated parallel, antiparallel, twist, bulge, or strand connection secondary structure and combinations of thereof. For example, a 20 amino acid peptide which self-assembles into 0-strands may comprise alternating valine and lysine residues flanking a tripeptide turn sequence, e.g., valine adjacent a proline and threonine turn sequence (V(d)PPT) (SEQ ID NO: 96), wherein (d)P designates D-proline (the D-stereoisomer of proline) and represents one amino acid residue.
[0126] When dissolved in low ionic strength and buffered aqueous solution, the exemplary peptide resides in an ensemble of random coil conformers due to electrostatic repulsions of the positively charged lysine residues. Upon increasing the ionic strength and / or pH of the solution, the lysine-based positive charge is relieved due to either screening of the charge or deprotonating a sufficient amount of the side chain amines. This exemplary action enables peptide folding into an amphiphilic 0-hairpin. In the folded state, the exemplary peptide self-assembles via lateral and facial associations of the hairpins to form a non-covalently crosslinked hydrogel containing 0-sheet rich fibrils. Thus, the self-assembling peptides may be designed to undergo hydrogelation under varying conditions through rational design of the peptide sequence.
[0127] The self-assembling peptides disclosed herein may assemble into a nano-porous tertiary structure. As disclosed herein, the nano-porous structure is a three-dimensional matrix containing pores having an average size of 1 - 1000 nm. The pores or voids may constitute between 10% and 90% of the three-dimensional matrix by volume. For example, the pores or voids may constitute 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the three-dimensional matrix by volume. The pores may be permeable and allow diffusion of liquid and / or gas. The nano-porous structure is constructed by physical crosslinks, allowing ionic bonds to be broken and reformed upon asserted stress. These nano-porous structure may allow for cells to attach and / or migrate through the matrix. The nano-porous structure may also mimic the endogenous extra-cellular matrix environment of tissues and, optionally, be selected to mimic a specific tissue.Docket No. G2093-7013WO
[0128] “Disassembly” of the peptides may refer to the ability of the peptide to assume a lower order structure after being exposed to a stimulus. Disassembly may also refer to the ability of the physically crosslinked peptide to temporarily break hydrophobic and disulfide bonds to assume a lower order structure after being exposed to a stimulus. For example, a tertiary structure protein may disassemble into a secondary structure protein, and further disassemble into a primary structure peptide. In accordance with certain embodiments, self-assembly and disassembly of the peptide may be reversible.
[0129] Preparations and formulations disclosed herein may generally be referred to as peptide preparations. The peptide preparations may include a self-assembling peptide and / or a self-assembled hydrogel as disclosed herein. The peptide preparation may include a cytocompatible and / or biocompatible solution. The preparation may include a buffer. While reference is made to a solution, it should be understood that the preparation may be in the form of a liquid, gel, or solid particle. In certain embodiments, for example, the preparation may be in the form of the assembled hydrogel. In other embodiments, the preparation may be in the form of a lyophilized powder.
[0130] The peptide preparation may further include one or more bioactive components for tissue engineering, such as, functionalized peptides, cells, media, serum, collagen and other structureimparting components, antibodies and antigens, bioactive small molecules, and other bioactive drugs. “Bioactivity” as described herein refers to the ability of a compound to impart a biological effect.
[0131] Cell containing preparations and formulations disclosed herein may be referred to as cell suspensions. Cell suspensions include a plurality of cells, e.g., living cells, suspended in a solution. The solution may be or comprise water, media, or buffer. The suspension may generally further comprise a self-assembling peptide and / or a self-assembled hydrogel, as disclosed herein. While reference is made to cells, it should be understood that the suspension may contain cell fragments and / or tissue, e.g. tissue grafts, in addition to or instead of the cells. For example, the suspension may contain live or dead cells or cell fragments, spheroids, and / or cell aggregates.
[0132] The cells may be isolated from living tissue and subsequently maintained and / or grown in cell culture. The cell culture conditions may vary, but generally include maintaining the cells in a suitable vessel with a substrate or medium that supplies the essential nutrients, e.g., amino acids, carbohydrates, vitamins, minerals, growth factors, hormones, and gases, e.g., CO2 and O2, and regulating the physio-chemical environment, e.g., pH, osmotic pressure, temperature. The cells may be maintained in live cell lines, e.g., a population of HeLa cells descended from a single cell and containing the same genetic makeup.Docket No. G2093-7013WO
[0133] The term “isolated,” as used herein, refers to material that is removed from its original or native environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated by human intervention from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and / or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of the environment in which it is found in nature.
[0134] As used herein, “treatment” of an injury, condition, or disease refers to reducing the severity or frequency of at least one symptom of that injury, condition, or disease, compared to a similar but untreated subject. Treatment can also refer to halting, slowing, or reversing the progression of an injury, condition, or disease, compared to a similar but untreated subject. Treatment may comprise addressing the root cause of the injury, condition, or disease and / or one or more symptoms.
[0135] “Management” of an injury, condition, or disease may refer to reducing the severity or frequency of at least one symptom of that injury, condition, or disease, to a tolerable level, as determined by the subject or a health care provider.
[0136] As used herein an effective amount refers to a dose or amount sufficient to achieve a desired result. For example, the effective amount may refer to a concentration sufficient to achieve selfassembly of the hydrogel and / or provide desired properties. An effective amount may refer to a dose sufficient to prevent advancement, or to cause regression of an injury, condition, or disease, or which is capable of relieving a symptom of an injury, condition, or disease, or which is capable of achieving a desired result. An effective amount can be measured, for example, as a concentration of peptide or other component in the preparation, solution, or buffer. An effective amount can be measured, for example, as a concentration of bioactive agent or an effect or byproduct of a bioactive agent. An effective amount can be measured, for example, as a number of cells or number of viable cells, or a mass of cells e.g., in milligrams, grams, or kilograms), or a volume of cells (e.g., in mm3).
[0137] Throughout this disclosure, formulation may refer to a composition or preparation or product. Administered “in combination,” as used herein, means that two (or more) different treatments are delivered to the subject during the course of the subject’s affliction with the injury, e.g., the preparation is delivered with a second agent after the subject has been diagnosed with the condition or injury and before the condition or injury has been cured or eliminated. In certain embodiments, administration in combination means the preparation additionally comprises one or more second agent. In some embodiments, the delivery of one treatment is still occurring when the delivery of the second begins, so that there is overlap. This is sometimes referred to herein as “simultaneous” orDocket No. G2093-7013WO
[0138] "concomitant” or “concurrent delivery.” In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. This is sometimes referred to herein as “successive” or “sequential delivery.”
[0139] In embodiments of either case, the treatment is more effective because of combined administration. For example, the second agent is a more effective, e.g., an equivalent effect is seen with less of the second agent, or the second agent reduces symptoms to a greater extent, than would be seen if the second agent were administered in the absence of the preparations disclosed herein, or the analogous situation is seen with the preparation. In some embodiments, delivery is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one treatment delivered in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive (i.e., synergistic). The delivery can be such that an effect of the administration of the preparation is still detectable when the second agent is delivered. In some embodiments, one or more treatment may be delivered prior to diagnosis of the patient with the injury.
[0140] As used herein, a subject may include an animal, a mammal, a human, a non-human animal, a livestock animal, or a companion animal. The term “subject” is intended to include human and non-human animals, for example, vertebrates, large animals, and primates. In certain embodiments, the subject is a mammalian subject, and in particular embodiments, the subject is a human subject.
[0141] Although applications with humans are clearly foreseen, veterinary applications, for example, with non-human animals, are also envisaged herein. The term “non-human animals” of the disclosure includes all vertebrates, for example, non-mammals (such as birds, for example, chickens; amphibians; reptiles) and mammals, such as non-human primates, domesticated, and agriculturally useful animals, for example, sheep, dog, cat, cow, pig, rat, among others. The term “non-human animals” includes research animals, for example, for example, mouse, rat, rabbit, dog, cat, pig, among others.
[0142] Properties of the Peptide Sequence and Secondary Structure
[0143] The peptides disclosed herein may have a sequence configured to fold into a desired secondary structure. The secondary structure may refer to a three-dimensional form of local segments of proteins. The secondary structure may comprise, for example, pleated sheet, helical ribbon, nanotube and vesicle, surface-assembled structure, and others. The peptides disclosed herein may have a sequence configured to self-assemble into a desired tertiary structure. The tertiary structureDocket No. G2093-7013WO
[0144] may refer to a three-dimensional organization of secondary structure protein forms. The tertiary structure may comprise, for example, three-dimensional matrix, porous matrix, nano-porous matrix.
[0145] In certain embodiments, the self-assembling peptides disclosed herein may be designed to adopt a desired secondary structure, such as a random coil, a-helix, P-sheet, P-turn, P-hairpin, fibrillar structure, nanotube, amorphous aggregate, or other conformation. Self-assembling peptides disclosed may be designed to adopt a secondary, for example, P-hairpin, and / or tertiary structure in response to one or more signals. Typically, after adopting the secondary structure, the peptides will self-assemble into a higher order structure, e.g.. a hydrogel. In certain embodiments, the selfassembly does not take place unless side chains on the peptide molecules are uniquely presented in the secondary structure conformation. The self-assembling peptides may assemble responsive to certain environmental conditions, e.g., pH, temperature, net charge, exposure to light, applied sound wave, or presence or absence of environmental factors. The environmental conditions which induce self-assembly may occur upon administration to a subject, e.g., upon contact with a target tissue. In some embodiments, the environmental conditions which induce self-assembly may occur upon combination of the peptide preparation with a buffer configured to induce self-assembly. The buffer may have a pH or composition configured to induce self-assembly. For example, the buffer may have a concentration of ions configured to induce self-assembly.
[0146] Self-assembly of the peptides disclosed herein may produce compact structures that exhibit biophysical structural relationships with the intended function of the peptide. For example, a compact tertiary structure may have a higher number of active amino acid residues per unit area, compared to unassembled peptides. In the particular example of antimicrobial peptides, the tertiary structure may enable a higher concentration of charged, e.g.. positively charged, amino acid residues per area, increasing antimicrobial properties (e.g., bacterial membrane destabilization and disruption).
[0147] In certain embodiments, the self-assembling peptide hydrogels may include those disclosed in and / or prepared by the methods disclosed in any of U.S. Patent Nos. 8,221,773; 7,884,185;
[0148] 8,426,559; 7,858.585; and 8,834,926, incorporated herein by reference in their entireties for all purposes. For example, the self-assembling peptide hydrogels may be or comprise any of SEQ ID NOS: 1-20 from U.S. Patent Nos. 8,221,773, 7,884,185, and 7,858,585; and SEQ ID NOS: 1-33 from U.S. Patent No. 8,834,926. Other self-assembling peptides are known and may be employed to bring about the methods disclosed herein.
[0149] The desired properties of the self-assembling peptides may be controlled by peptide design. The self-assembling peptides may be small peptides, e.g., from about 6 to about 200 residues or from about 6 to about 50 residues, from about 10 to about 50 residues, or from about 4 to about 40Docket No. G2093-7013WO
[0150] residues. In certain embodiments, the peptide may have between about 16 and 24 residues, for example, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, or about 24 amino acid residues. Any of the amino acid residues may be a D isoform. Any of the amino acid residues may be an L isoform.
[0151] Self-assembling peptides disclosed herein may be designed to be substantially amphiphilic when assembled into the tertiary structure. “Amphiphilic” molecules, e.g., macromolecules or polymers, as disclosed herein, typically contain hydrophobic and hydrophilic components. Peptide amphiphiles are one exemplary class of amphiphilic molecules. Peptide amphiphiles are peptide-based molecules that typically have the tendency to self-assemble into high-aspect-ratio nanostructures under certain conditions. The exemplary conditions may comprise selected pH, temperature, and ionic strength values. One particular type of peptide amphiphiles comprise alternating charged, neutral, and hydrophobic residues, in a repeated pattern, for example, as disclosed herein. A combination of intermolecular hydrogen bonding and hydrophobic and electrostatic interactions may be designed to form well-defined self-assembled nanostructures by assembly of the disclosed peptide amphiphiles.
[0152] The self-assembling peptides may include additional amino acids, for example, an epitope. For example, the self-assembling peptides may include additional functional groups, optionally selected by peptide design. Exemplary functional groups disclosed herein comprise a biologically derived motif, for example, having an effect on biological processes such as cell signal transduction, cell adhesion in the extra-cellular matrix (ECM), cell growth, and cell mobility. The peptide may include one or more modifications, for example, a linker or spacer.
[0153] In some embodiments, at least one of the N-terminus and the C-terminus may be modified. For example, at least one of the N-terminus and the C-terminus may be amidated. At least one of the N-terminus and the C-terminus may comprise a cysteine moiety. At least one of the N-terminus and the C-terminus may be acetylated. In certain exemplary embodiments, the C-terminus may be amidated and / or the N-terminus may be acetylated. In some embodiments, at least one of the N-terminus and the C-terminus may be free. For example, in some embodiments, the peptide has a free amine at the N-terminus. In some embodiments, the peptide has a free carboxyl group at the C-terminus.
[0154] One exemplary amidated self-assembling peptide is VKVRVRVRV(d)PPTRVRVRVKV-NH2 (SEQ ID NO: 2). Any of the peptides disclosed herein may be amidated. One exemplary acetylated and amidated self-assembling peptide is Ac-VKVRVRVRV(d)PPTRVRVRVKV-NH2 (SEQ ID NO: 2). Any of the peptides disclosed herein may be amidated, acetylated, or both.Docket No. G2093-7013WO
[0155] Additionally, one or both ends of any of the peptides disclosed herein may be free. For example, the N-terminus may be free and / or the C-terminus may be free.
[0156] In general, the self-assembling peptides may have a folding group configured to adopt the secondary and / or higher order structure. Exemplary self-assembling peptides may have a folding group designed to adopt a P-turn or P-hairpin secondary structure. Exemplary self-assembling peptides may have a folding group designed to adopt a three-dimensional nano-porous matrix tertiary structure. Self-assembling peptides disclosed herein may be designed to adopt a P-turn or P-hairpin secondary structure and / or nano-porous matrix tertiary structure in response to one or more environmental stimulus at the target site, e.g., at a topical or parenteral site. The self-assembling peptides may also be designed to self-assemble into a range of other self-assembled structures, such as spherical micelles, vesicles, bilayers (lamellar structures), nanofibers, nanotubes, and ribbons.
[0157] The self-assembly folding group may have between about 2 and about 200 residues, for example, between about 2 and about 50 residues, between about 4 and about 40 residues, between about 10 and about 30 residues, between about 16 and about 24 residues, for example, about 20 residues.
[0158] In accordance with some embodiments, the self-assembling folding group may include hydrophobic amino acids. “Hydrophobic” amino acid residues are those which tend to repel water. Such hydrophobic amino acids may include glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, threonine, and tryptophan. In certain embodiments, the hydrophobic amino acid residues may comprise valine.
[0159] The folding group may be functionalized by addition of other functional residues as described herein, or conserved for self-assembly. Exemplary functional residues include basic, neutral, aliphatic, aromatic, and polar amino acid residues.
[0160] The folding group may have a plurality of basic, neutral, aliphatic, aromatic, polar, charged amino acid residues. The folding group may have a plurality of hydrophobic amino acid residues arranged in a substantially alternating pattern with non-hydrophobic amino acid residues. In certain embodiments, the folding group may have a plurality of hydrophobic amino acid residues arranged in a substantially alternating pattern with a plurality of charged amino acid residues.
[0161] The folding group may comprise a turn sequence. The turn sequence may include one or more internal amino acid residues within the folding group. In certain embodiments, the turn sequence may be substantially centrally located within the folding group. The turn sequence may be designed to adopt a P-turn or P-hairpin secondary structure.Docket No. G2093-7013WO
[0162] The turn sequence may have between about 2 and about 20 residues, for example, between about 2 and about 10 residues, between about 2 and about 8 residues, between about 2 and about 5 residues, for example, about 2 residues, about 3 residues, about 4 residues, or about 5 residues.
[0163] In exemplary embodiments, the turn sequence may include one or more of proline, aspartic acid, threonine, and asparagine. The turn sequence may include D-proline and / or L- proline. In some embodiments, the turn sequence may have 1-4 proline residues, for example, 1 proline residue, 2 proline residues, 3 proline residues, or 4 proline residues.
[0164] The self-assembling the folding group may comprise a first arm and a second arm flanking the turn sequence, each arm comprising alternating hydrophobic amino acid residues and charged amino acid residues. The design of the first arm and second arm, in combination with the selected turn sequence, may enable folding into the desired secondary and / or higher order structure. In certain embodiments, the design of the first arm and second arm may be selected to provide a desired charge and / or charge density of the peptide or hydrogel.
[0165] Exemplary self-assembling peptides may have a folding group sequence comprising [AY]N[T][YA]M, where A is 1-3 amino acids selected from one or more of basic, neutral, aliphatic, aromatic, polar, and charged amino acids, Y is 1-3 hydrophobic amino acids, T is 0-8, for example, 2-8 turn sequence amino acids, and N and M are each independently between 2 and 10. Y amino acids may independently be selected from glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, threonine, and tryptophan. In some embodiments, the folding group sequence may be Y[AY]N[T][YA]MY-NH2.
[0166] Certain exemplary self-assembling peptides may have a folding group sequence comprising [XY]N[T][YX]M, where X is 1-3 charged amino acids, Y is 1-3 hydrophobic amino acids, T is 0-8, for example, 2-8 turn sequence amino acids, and N and M are each independently between 2 and 10. X amino acids may independently be selected from arginine, lysine, tryptophan, and histidine. Y amino acids may independently be selected from glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, threonine, and tryptophan. In the exemplary sequence, [XY]N and [YX]M would be the first arm and the second arm, respectively. In some embodiments, the folding group sequence may be Y[XY]N[T][YX]MY-NH2.
[0167] Certain exemplary self-assembling peptides may have a folding group sequence comprising [XY]N[T][XY]M, where X is 1-3 charged amino acids, Y is 1-3 hydrophobic amino acids, T is 0-8, for example, 2-8 turn sequence amino acids, and N and M are each independently between 2 and 10. X amino acids may independently be selected from arginine, lysine, tryptophan, and histidine. Y amino acids may independently be selected from glycine, alanine, valine, leucine, isoleucine, proline,Docket No. G2093-7013WO
[0168] phenylalanine, methionine, threonine, and tryptophan. In the exemplary sequence, [XY]N and [XY]M would be the first arm and the second arm, respectively. In some embodiments, the folding group sequence may be Y[XY]N[T][XY]M-NH2. One exemplary self-assembling peptide may have a folding group comprising YXYXYXYXYTXYXYXYXY-NH2.
[0169] In certain exemplary embodiments, the self-assembling peptide may have a sequence comprising Y[XY]N[T][XY]M-NH2, where Y is valine, X is selected from lysine and arginine, T is one or more turn sequence residues, and N and M are each 4. In some embodiments, T may comprise proline and / or threonine.
[0170] The self-assembling peptide may comprise 0, 2, 4, 6, or 8 lysine residues. The selfassembling peptide may comprise 0, 2, 4, 6, or 8 arginine residues. The lysine and arginine residues may be independently positioned at any one or more or all positions selected from positions 2, 4, 6, 8, 13, 15, 17, 19.
[0171] The self-assembling peptide may comprise a turn sequence at positions 10-12. The selfassembling peptide may comprise 0, 1, or 2 proline residues. The self-assembling peptide may comprise 0, 1, or 2 threonine residues. The proline and threonine residues may be independently positioned at any one or more or all positions selected from positions 10, 11, 12. One or more of the proline or threonine residues may be the D-enantiomer. One or more of the proline or threonine residues may be the L-enantiomer. In exemplary embodiments, the turn-sequence residues may be (d)PPT (as shown in SEQ ID NO: 96 adjacent a valine residue), where (d)P is the D-enantiomer of proline and P and T are each the L-enantiomer of proline and threonine, respectively.
[0172] Exemplary peptides include VKVKVKVKV(d)PPTKVKVKVKV-NH2(SEQ ID NO: 1) (8 lysine residues, 0 arginine residues); VKVKVRVKV(d)PPTKVKVRVKV-NH2(SEQ ID NO: 10) (2 arginine residues, 6 lysine residues); VKVKVRVRV(d)PPTRVRVKVKV-NH2(SEQ ID NO: 99) (4 arginine residues, 4 lysine residues; VKVRVRVRV(d)PPTRVRVRVKV-NH2 (SEQ ID NO: 2) (6 arginine residues, 2 lysine residues); VRVRVRVKV(d)PPTKVRVRVRV-NH2 (SEQ ID NO: 5) (6 arginine residues. 2 lysine residues); and VRVRVRVRV(d)PPTRVRVRVRVNH2(SEQ ID NO: 100) (8 arginine residues, 0 lysine residues).
[0173] One exemplary self-assembling peptide may have a folding group comprising -RYRYRYTYRYRYR- where R is an arginine residue, Y is 1-3 hydrophobic amino acids, and T is 0-6, for example, 2-6 turn sequence amino acids.
[0174] One exemplary self-assembling peptide may have a folding group comprising -VXVXVXVXVTXVXVXVXV- where V is a valine residue, X may be independently selected from charged and neutral amino acid residues serine, glutamic acid, lysine, tryptophan, and histidine, andDocket No. G2093-7013WO
[0175] T is 0-8, for example, 2-8 turn sequence amino acids. In some embodiments, the exemplary folding group may comprise a series of hydrophobic valine amino acid residues alternating with independently selected hydrophilic and / or neutral amino acid residues.
[0176] One exemplary self-assembling peptide may have a folding group comprising -KYKYKYTYKYKYK- where R is an arginine residue, Y is 1-3 hydrophobic amino acids, and T is 0-6, for example, 2-6 turn sequence amino acids.
[0177] One exemplary self-assembling peptide may have a folding group comprising -VZVZVZVTVZVZVZV- where V is a valine residue, Z is 1-3 hydrophilic amino acids, and T is 0-6, for example, 2-6 turn sequence amino acids.
[0178] Exemplary self-assembling peptides may have a turn sequence comprising 0-8 turn sequence amino acids, for example, 2-8 turn sequence amino acids, for example 2-5 turn sequence amino acids. The turn sequence amino acids may be selected from proline, for example D-proline and / or L-proline, aspartic acid, and asparagine. In some embodiments, the turn sequence may be (d)PP, (d)PG, or NG. The turn sequence may optionally also include a threonine residue. In some embodiments, the self- assembling peptide may be free of turn sequence amino acids.
[0179] Exemplary self-assembling peptides having a turn sequence include VKVRVRVRV(d)PPTRVRVRVKV-NH2(SEQ ID NO: 2); VLTKVKTKV(d)PPTKVEVKVLV-NH2(SEQ ID NO: 16); VKVKVKVKV(d)PPTKVKVKVKV-NH2(SEQ ID NO: 1);
[0180] VKVKVRVKV(d)PPTKVKVRVKV-NH2(SEQ ID NO: 10); VKVKVRVRV(d)PPTRVRVKVKV-NH2(SEQ ID NO: 99); VRVRVRVRV(d)PPTRVRVRVRVNH2(SEQ ID NO: 100); and VRVRVRVKV(d)PPTKVRVRVRV-NH2(SEQ ID NO: 5).
[0181] In the exemplary peptides, the tripeptide turn sequence was selected to adopt a type II’ turn and positioned within the middle of the peptide sequence adjacent a valine residue (-V(d)PPT-) (SEQ ID NO: 96). This four-residue sequence occupies the i, +1, z+2 and z+3 positions of the turn. The heterochiral sequence ((d)P (z+1) - P (z+2)) dipeptide was selected for its tendency to adopt dihedral angles consistent with type IT turns. Incorporation of a bulky P-branched residue (valine) at the z position of the turn sequence enforces the formation of a trans prolyl amide bond at the z+1 position. The placement of valine at this position is selected to design against the formation of a cis prolyl bond, which results in -strands that adopt an extended conformation rather than the intended hairpin. Threonine exhibits a statistical propensity to reside at the z+3 position. Therefore, threonine was selected to be incorporated at this position within the turn sequence, which bears a side-chain hydroxyl group capable of hydrogen bonding to the amide backbone carbonyl at the z position, to further stabilize the turn.Docket No. G2093-7013WO
[0182] The exemplary folding peptides may be designed to include high propensity P-sheet forming residues flanking the type II’ turn sequence. The selection of alternation of hydrophobic and hydrophilic residues along the strands provides an amphiphilic P-sheet when the peptide folds. For example, lysine may be chosen as a hydrophilic residue to provide a side chain pKa value of about 10.5. Side chain amines are generally protonated when dissolved under slightly acid conditions, forming unfavorable electrostatic interactions between P-strands of the hairpin and inhibiting peptide folding and self-assembly. However, as pH is increased to about pH 9, a sufficient portion of the lysine side chains become deprotonated allowing the peptide to fold into an amphiphilic P-hairpin. The electrostatic interactions may be employed to design pH responsiveness of the disclosed peptides.
[0183] While not wishing to be bound by theory, it is believed the amphiphilic P-hairpin is stabilized in the intramolecular folded state by van der Waals contacts between neighboring amino acid side chains within the same hairpin. The formation of intramolecular hydrogen bonds between cross P-strands of the hairpin and the propensity for the turn sequence to adopt at type IT turn may further stabilize the folded conformation. Once in the folded state, the lateral and facial associations of the P-hairpins may be selected to design self-assembly. For example, lateral association of P-hairpins promotes the formation of intermolecular hydrogen bonds and van der Waals contacts between neighboring amino acids.
[0184] Any of the charged, hydrophobic, polar, or amphipathic amino acids disclosed herein may derive one or more of their properties from the composition of the biocompatible solution.
[0185] Hydrophobic amino acids are those which tend to repel water. Hydrophobic amino acids include alanine, valine, leucine, isoleucine, proline, tyrosine, tryptophan, phenylalanine, methionine, and cysteine. The hydrophobic amino acids may be independently selected from alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, cysteine, and combinations thereof. In some embodiments, the hydrophobic amino acids comprise valine.
[0186] Charged amino acids are those which tend to have an electric charge under the given conditions. Charged amino acids may have side chains which form salt bridges. Charged amino acids include alanine, valine, leucine, isoleucine, proline, phenylalanine, cysteine, arginine, lysine, histidine, aspartic acid, and glutamic acid. The folding group may comprise 2-10 charged amino acids, for example 2-8 charged amino acids.
[0187] The charged amino acids may be positively charged amino acids. The folding group may comprise 2-10 charged amino acids, for example 2-8 charged amino acids. The positively charged amino acids may be independently selected from arginine, lysine, histidine, and combinationsDocket No. G2093-7013WO
[0188] thereof. The folding group may comprise 2-8 arginine residues, lysine residues, or a combination of arginine and lysine residues. In some embodiments, the folding group may comprise 6 positively charged residues selected from arginine, lysine, or a combination of arginine and lysine.
[0189] The charged amino acids may be negatively charged amino acids. The folding group may comprise 2-10 negatively charged amino acids, for example, 2-8 negatively charged amino acids. In some embodiments, the negatively charged amino acids may be independently selected from aspartic acid, glutamic acid, and combinations thereof.
[0190] Polar amino acids are those which have an uneven charge distribution. Polar amino acids may tend to form hydrogen bonds as proton donors or acceptors. Polar amino acids include glutamine, asparagine, histidine, serine, threonine, tyrosine, and cysteine.
[0191] Amphipathic amino acids are those which have both a polar and non-polar component.
[0192] Amphipathic amino acids may be found at the surface of proteins or lipid membranes. Amphipathic amino acids include tryptophan, tyrosine, and methionine.
[0193] Exemplary self-assembling peptides may have a folding group sequence of any of SEQ ID NOS: 1-23 or SEQ ID NOS: 97-100.
[0194] Exemplary self-assembling peptides which have shear-thinning properties include VKVRVRVRV(d)PPTRVRVRVKV-NH2, (SEQ ID NO: 2) and VKVRVRVRV(d)PPTRVEVRVKV-NH2(SEQ ID NO: 97) (which has a single substitution of glutamic acid at position 15 on the hydrophilic face). The glutamic acid substitution results in a faster rate of gelation of the self-assembling peptide gel in the presence of ionic salts in the biocompatible solution. The negatively charged glutamic acid lowers the overall positive charge of the peptide and enables faster folding and self-assembly.
[0195] Exemplary self-assembling peptides which have shear-thinning properties that can be tuned for net peptide charge include VKVRVRVRV(d)PPTRVEVRVKV-NH2(SEQ ID NO: 97), and VKVKVKVKV(d)PPTKVEVKVKV-NH2(SEQ ID NO: 15), (which has an arginine substituted for lysine on the hydrophilic face). The lysine substitution lowers the peptide net charge at physiological pH that allows for better mammalian cell cytocompatibility when compared to peptides with high arginine content (higher net charge).
[0196] Exemplary self-assembling peptides which have shear-thinning properties that can be tuned for peptide gels with faster rate of gelation and increased stiffness include FKFRFRFRV-(d)PPTRFRFRFKF-NH2(SEQ ID NO: 98), (which has valine substituted for phenylalanine on the hydrophobic face). The phenylalanine substitution increases the hydrophobic face of the peptide that allows for stiffer and faster gelation of peptide gels.Docket No. G2093-7013WO
[0197] Exemplary self-assembling peptides which have shear-thinning properties include enantiomer forms of the exemplary sequences listed above, such as an enantiomer form of VKVRVRVRV(d)PPTRVRVRVKV-NH2, (SEQ ID NO: 2), (d)V(d)K(d)V(d)R(d)V(d)R(d)V(d)R(d)V(L)P(d)P (d)T(d)R(d)V(d)R(d)V(d)R(d)V(d)K(d)V-NH2. (which has D isoforms of the sequence and an L isoform of P). The isoform substitution may provide control of peptide degradation and increased stability without compromising peptide net charge at physiological pH. The sequence may provide better compatibility with mammalian cells. The peptide may be a complete enantiomer (as shown above) or a partial enantiomer such that any one or more of the amino acids may be an enantiomer of the sequences listed above.
[0198] Other exemplary self-assembling peptides include Ac-VEVSVSVEV(d)PPTEVSVEV EVGGGGRGDV-NH2(SEQ ID NO: 22) and VEVSVSVEV(d)PPTEVSVEVEV-NH2(SEQ ID NO: 23). The self-assembling peptide may comprise at least one guanidine moiety. The guanidine moiety may be associated with an organic molecule which makes up part of the peptide chain. In exemplary embodiments, a guanidine group may be incorporated as part of the side chain of an arginine residue. However, the peptide may comprise guanidine moieties which are not associated with arginine residues.
[0199] A guanidine moiety is generally a highly polar group which, when positioned on a cationic peptide, may allow for pairing with hydrophobic and hydrophilic groups forming salt bridges and hydrogen bonds. Such a peptide may display a high capacity to penetrate cell membranes and provide antimicrobial activity. The guanidine moiety may also promote peptide stability by improving peptide folding, physical characteristics and thermal stability of the peptide and / or hydrogel.
[0200] The peptide may generally have 20-50% guanidium content, as measured by number of guanidine groups by total number of amino acid residues of the peptide. For instance, an exemplary peptide sequence having 20 amino acid residues, of which 6 are arginine residues having a guanidine group, has 30% guanidium content. The exemplary peptides may penetrate and disrupt cell membranes.
[0201] Properties of the Peptide Hydrogel Preparation
[0202] The preparation may generally comprise the self-assembling peptide in a biocompatible solution. For example, the peptide may be dissolved or substantially dissolved in the biocompatible solution. The preparation may comprise between about 0.01% w / v and about 10.0% w / v of theDocket No. G2093-7013WO
[0203] peptide. The preparation may be formulated for a target indication. For instance, the concentration of the self-assembling peptide may be selected based on a target indication.
[0204] Exemplary preparations may comprise between about 0.01% w / v and about 10.0% w / v of the peptide, for example, between about 0.1% w / v and about 10.0% w / v of the peptide, between about 0.1% w / v and about 8.0% w / v of the peptide, between about 0.25% w / v and about 6.0% w / v of the peptide, between about 0.5% w / v and about 6.0% w / v of the peptide. When the peptide is purified, the preparation may comprise up to about 6.0% w / v of the peptide. In certain embodiments, the preparation may comprise less than about 3.0% w / v of the peptide, for example, between about 0.25% w / v and about 3.0% w / v of the peptide, between about 0.25% w / v and about 2.0% w / v of the peptide, between about 0.25% w / v and about 1.25% w / v of the peptide, or between about 0.5% w / v of the peptide and about 1.5% w / v of the peptide. The preparation may comprise between about 0.01% w / v and about 0.1% w / v of the peptide, between about 0.1% w / v and about 0.5% w / v, between about 0.5% w / v and about 1.0% w / v of the peptide, between about 0.7% w / v and about 2.0% w / v of the peptide, between about 0.1% w / v and about 2.5% w / v of the peptide, or between about 0.7% w / v and about 0.8% w / v of the peptide. For instance, the preparation may comprise about 0.01% w / v, about 0.1% w / v, about 0.25% w / v, about 0.5% w / v, about 0.7% w / v, about 0.75% w / v, about 0.8% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v, about 2.5% w / v, or about 3.0% w / v of the peptide. In particular embodiments, the preparation may comprise less than about 1.5% w / v of the peptide. The preparation may comprise less than about 1.25% w / v of the peptide or less than about 1.0% w / v of the peptide. In one exemplary embodiment, the preparation may comprise about 0.75% w / v of the peptide.
[0205] After combination with the buffer, the hydrogel may have between about 0.05% w / v and 6.0% w / v of the peptide. For example, the hydrogel may have between about 0.1% w / v, and 6.0% w / v of the peptide, between about 0.25% w / v and 6.0% w / v of the peptide, between about 1.5% w / v and 6.0% w / v of the peptide, between about 0.1% w / v and 2.5% w / v of the peptide, between about 0.25% w / v and 3.0% w / v of the peptide, between about 0.25% w / v and 1.0% w / v of the peptide, between about 0.25% w / v and 0.5% w / v of the peptide, or between about 0.3% w / v and 0.4% w / v of the peptide. The peptide preparation and buffer may be combined to form the hydrogel at a ratio of between about 2: 1 to 0.5:1 peptide preparation to buffer. In some embodiments, the peptide preparation and buffer may be combined to form the hydrogel at a ratio of about 1:1.
[0206] The peptides in the preparation may be purified. As disclosed herein, “purified” with respect to the peptides in the preparation, may refer to peptide samples treated for removal of incorrect peptides. Peptide purity may refer to the amount of correct peptide relative to all peptides in aDocket No. G2093-7013WO
[0207] sample. Correct peptides are those peptides which have a sequence matching the desired sequence. Incorrect peptides are those peptides which have at least one synthesis error or failure. Specifically, incorrect peptides may have at least one amino acid moiety which does not match the desired sequence. In some embodiments, the peptides may be at least 50% purified, for example, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or at least 99.9%.
[0208] The preparation may be purified. As disclosed herein, “purified” with respect to the preparation, may refer to compositions treated for removal of contaminants. In particular, the purified preparation may have a composition suitable for clinical application. For example, the preparation may be purified to meet health and / or regulatory standards for clinical administration. The preparation may be at least 80% purified, for example, at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or at least 99.9%.
[0209] In certain embodiments, the preparation may be purified to remove or reduce residual organic solvent content from solid phase synthesis of the peptides. The preparation may comprise less than 20% residual organic solvent by weight. The preparation may comprise less than 15% residual organic solvent by weight. The preparation may comprise less than 10% residual organic solvent by weight. For example, the preparation may comprise less than 8%, less than 5%, less than 2%, less than 1%, or less than 0.1% residual organic solvent by weight. Exemplary organic solvents which may be removed or reduced from the synthesized peptide include trifluoroacetic acid (TFA), acetonitrile, isopropanol, N,N-Dimethylformamide, triethylamine, Ethyl Ether, and acetic acid.
[0210] The purified preparation may be substantially free of Trifluoroacetic acid (TFA). For example, the purified preparation may have less than 1% w / v residual TFA, or between about 0.005% w / v and 1% w / v residual TFA.
[0211] The purified preparation may be substantially free of acetonitrile. In some embodiments, the purified preparation may have less than about 410 ppm residual acetonitrile. The purified preparation may have between about 0.005 ppm and about 410 ppm residual acetonitrile.
[0212] The purified preparation may be substantially free of isopropanol. In some embodiments, the purified preparation may have less than about 400 ppm residual isopropanol. The purified preparation may have less than about 100 ppm residual isopropanol. The purified preparation may have between about 0.005 ppm and 100 ppm residual isopropanol.
[0213] The purified preparation may be substantially free of N,N-Dimethylformamide. In some embodiments, the purified preparation may have less than about 880 ppm residual N,N-Docket No. G2093-7013WO
[0214] Dimethylformamide. The purified preparation may have between about 0.005 ppm and about 880 ppm residual N,N-Dimethylformamide.
[0215] The purified preparation may be substantially free of triethylamine. In some embodiments, the purified preparation may have less than about 5000 ppm residual triethylamine. The purified preparation may have between about 0.005 ppm and about 5000 ppm residual triethylamine.
[0216] The purified preparation may be substantially free of Ethyl Ether. In some embodiments, the purified preparation may have less than about 1000 ppm residual Ethyl Ether. The purified preparation may have between about 0.005 ppm and about 1000 ppm residual Ethyl Ether.
[0217] The purified preparation may be substantially free of acetic acid. For example, the purified preparation may have less than 2% w / v residual acetic acid, for example, less than 1% w / v residual acetic acid, less than 0.5% w / v residual acetic acid, less than 0.1% w / v residual acetic acid, between about 0.0001% w / v and 2% w / v residual acetic acid, or between about 0.005% w / v and 0.1% w / v residual acetic acid.
[0218] In general, the purified preparation and / or hydrogel may have properties consistent with regulatory limits defined by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).
[0219] The biocompatible solution of the preparation may refer to a substantially liquid carrier for the peptide. The biocompatible solution may generally be an aqueous solution. The biocompatible solution may comprise water, for example, deionized water. Deionized water may have a resistivity of greater than about 18 MQ and a conductivity of less than about 0.056 pS at 25 °C. Deionized water may have a maximum endotoxin specification of 0.03 endotoxin units (EU) / ml and 1 CFU / mL microbial action or less. Deionized water may have a total organic carbon (TOC) concentration of 10 ppb or less. The biocompatible solution may comprise pharmaceutical grade water. Pharmaceutical grade water may have 500 ppb total organic carbon (TOC) or less and 100 CFU / ml microbial action or less. The biocompatible solution may comprise injection grade water. Injection grade water may have a maximum endotoxin specification of 0.25 endotoxin units (EU) / ml and 10 CFU / 10 ml microbial action or less. In certain embodiments, the preparation or biocompatible solution may be substantially free of chloride ions.
[0220] In some embodiments, for example, if the preparation has been lyophilized or dried, e.g., freeze-dried, the preparation may be in dried form. The preparation may comprise little to no residual moisture. Thus, the preparation may be substantially free of the biocompatible solution.
[0221] The preparation or peptide may comprise counterions. As disclosed herein, a counterion may refer to a charge balancing ion. The preparation or peptide may have an effective amount ofDocket No. G2093-7013WO
[0222] counterions to render the preparation substantially electrically neutral. The preparation or peptide may have an effective amount of counterions to render the preparation substantially biocompatible and / or stable. The preparation or peptide may have an effective amount of counterions to control repulsion of anionic or cationic residues of the peptide. The concentration of counterions may be dependent on the peptide sequence and concentration of the peptide and any additives. In exemplary embodiments, the peptide may comprise between 0.1-20% counterions. Additionally, the charge of the counterions may be dependent on the charge of the peptide and any additives. Thus, the counterions may be anions or cations. In general, the counterions may be cytocompatible. In certain embodiments, the counterions may be biocompatible. For instance, the counterions may comprise acetate, citrate, ammonium, fluoride, or chloride. In other embodiments, the preparation or peptide may be substantially free of chloride counterions.
[0223] In exemplary embodiments, the preparation or peptide may comprise an effective amount of acetate counterions. In particular, preparations having a peptide concentration which comprises residual TFA may have an amount of acetate counterions sufficient to balance the residual TFA. Briefly, TFA is commonly used to release synthesized peptides from solid-phase resins. TFA is also commonly used during reversed-phase HPLC purification of peptides. However, residual TFA or fluoride may be toxic and undesirable in peptides intended for clinical use. Furthermore, TFA may interact with the free amine group at the N-terminus and side chains of positively charged residues (for example, lysine, histidine, and arginine). The presence of TFA-salt counterions in the peptide preparation may be detrimental for biological material and may negatively affect the accuracy and reproducibility of the intended peptide activity.
[0224] TFA-acetate salt exchange by acetate or hydrochloride may be employed to counteract some or all of the negative effects of TFA described above. The inventors have determined the acetate counterion is surprisingly well suited for maintaining biological activity of the peptide preparation and for controlling solubility of the peptide and charge for self-assembly of the peptide. Furthermore, acetic acid (pKa = 4.5) is weaker than both trifluoroacetic acid (pKa about 0) and hydrochloric acid (pKa = -7). Acetate counterions may additionally control pH of the peptide preparations to be physiologically neutral.
[0225] The preparation may have variable hydrogelation kinetics. In accordance with certain embodiments, the hydrogelation kinetics of the preparation may be designed for a particular mode of administration. The preparation may be administered as a liquid. The preparation may be administered as a solid or semi-solid. The preparation may be administered as a gel. The preparation may be administered as a combination of hydrogel suspended in a liquid. The preparation may have aDocket No. G2093-7013WO
[0226] variable apparent viscosity. For instance, the preparation may have an apparent viscosity effective to allow injection under the conditions of administration. In certain embodiments, the preparation may have an apparent viscosity which decreases with increasing shear stress.
[0227] The preparation may be configured to reversibly self-assemble and disassemble in response to applied stress, for example, applied mechanical force. The solid or gel preparation may become disrupted with increasing applied stress, to be later restored once the applied stress is reduced. The solid or gel may become fluid in response to applied stress, for example, during delivery through a delivery device. The peptide may be capable of undergoing sequential phase transitions in response to applied stress. The peptide may be capable of recovering after each one or more sequential phase transitions.
[0228] The preparation may be configured to reversibly self-assemble and disassemble responsive to at least one of change in temperature, change in pH, contact with an ion chelator, dilution with a solvent, applied sound wave, lyophilization, vacuum drying, and air drying. The administered fluid may conform to tissue voids before reforming as a solid or gel. Thus, the solid or gel preparation may be injectable, flowable, or sprayable under the appropriate shear stress. Once administered, the preparation may be restored to a solid or gel form, substantially conforming to the target site. The formation may occur within less than a minute, about one minute, less than about 2 minutes, less than about 3 minutes, less than about 5 minutes, or less than about 10 minutes. The formation may occur within about one minute, less than about 30 seconds, less about 10 seconds, or about 3 to 5 seconds.
[0229] As shown in FIG. 9, net charge may be quantified as a function of pH value. The exemplary peptide measured in FIG. 9 is an arginine-rich peptide having two lysine residues. The exemplary peptide of FIG. 9 has a net charge of +9 at a pH of 7. For example, the peptide may have a net charge between -10 to +11 at pH 7.4, for example, -7 to +9 at pH 7.4. As disclosed herein, “net charge” may refer to a total electric charge of the peptide as a biophysical and biochemical property, typically as measured at a pH of 7.4.
[0230] The peptide may have a net charge of from -10 to +11, -9 to +11, or -7 to +11 at pH 7.4. In some embodiments, the peptide may have a net charge of from +2 to +9, for example, +5 to +9 or +7 to +9. The purified peptide may have a charge of about +5, +6, +7, +8, +9, +10, or +11 at pH 7.4. Exemplary peptides having a charge of +5 to +9 include VLTKVKTKV(d)PPTKVEVKVLV (SEQ ID NO: 16), VKVRVRVRV(d)PPTRVRVRVKV (SEQ ID NO: 2), and VKVRVRVRV(d)PPTRVEVRVKV (SEQ ID NO: 97).
[0231] In other embodiments, the peptide may be substantially neutral.Docket No. G2093-7013WO
[0232] In other embodiments, the peptide may have a net negative charge. For example, the peptide may have a net charge of from -7 to 0, for example, -7 to -2, or -5 to -2, for example, -7, -6, -5, -4, -3, -2, -1, or 0. An exemplary peptide having a net negative charge is VEVSVSVEV(d)PPTEVSVEVEV (SEQ ID NO: 23).
[0233] As shown in FIG. 10, a single substitution of glutamic acid in the peptide sequence may alter net peptide charge from +7 VKVKVKVKV(d)PPTKVEVKVKV (SEQ ID NO: 15) (top panel) to +9 VKVRVRVRV(d)PPTRVRVRVKV (SEQ ID NO: 2) (bottom panel) at pH 7, as well as alter isoelectric point from 11.45 to 14. Net charge may be selected by peptide design. Design of electrostatic charge in the peptide hydrogel may allow control of charge interaction with cell membrane and proteins.
[0234] The peptide may be designed to have a charge that adsorbs and / or promotes deactivation of proteins at a target site of administration. For instance, positively charged peptide hydrogels may promote adsorption of negatively and neutrally charged molecules such as small molecules, proteins, and extravesicular membranes. Negatively charged peptide hydrogels may promote adsorption of positively and neutrally charged molecules such as small molecules, proteins, and extravesicular membranes. Furthermore, the peptide may be designed to have regions of positive, neutral, or negative charge, to varying degrees. In certain embodiments, the peptide charge may be designed such that when placed into a rich solution of charged molecules, the peptide may soak out or absorb the molecules into the hydrogels attaching the molecules to the peptides by adsorption. FIG. 3 is a microscopy image showing negatively charged Trypan blue adsorbed on a positively charged hydrogel.
[0235] The peptide may have greater than 70% w / v, greater than 80% w / v, or greater than 90% w / v nitrogen, for example, between 70% w / v and 99.9% w / v nitrogen.
[0236] The peptide may have a bacterial endotoxin level of less than about 10 EU / mg, for example, less than about 5 EU / mg, less than about 2 EU / mg, or less than about 1 EU / mg. In other embodiments, the purified peptide may have an endotoxin level of between about -0.010 to -0.015 EU / ml. For instance, the purified peptide may have an OD at 410 nm of between 0.004 to 0.008, for example, about 0.006. The peptide hydrogel may have an OD at 410 nm of between 0.010 to 0.020, for example, about 0.015. In some embodiments, the purified peptide and / or preparation may be substantially free of endotoxins.
[0237] The peptide in the biocompatible solution may have a water content of between about 1 % w / v and about 20% w / v, for example, at least about 10% w / v, or less than about 15% w / v.Docket No. G2093-7013WO
[0238] The peptide may have an isoelectric point of between about 7-14. For example, the purified peptide may have an isoelectric point of about 7, 8, 9, 10, 11, 12, 13, or 14.
[0239] The peptide may be configured to self-assemble into a hydrogel having a shear modulus of between about 2 Pa to 3500 Pa as determined by rheology testing. For example, the purified peptide may self-assemble into a hydrogel having a shear modulus of greater than 100 Pa, between 100 Pa and 3500 Pa, between 100 Pa and 3000 Pa, between 2 Pa and 1000 Pa, or between 2 Pa and 500 Pa. For example, a formulation having 0.75% w / v peptide may have a shear modulus of between about 2 Pa and 500 Pa. A formulation having 1.5% w / v peptide may have a shear modulus of between about 100 Pa and 3000 Pa. A formulation having 3.0% w / v peptide may have a shear modulus of between about 1000 Pa and 10000 Pa. Thus, shear modulus of the hydrogel may be controlled by selection of peptide concentration in the formulation.
[0240] The peptide may be designed to adopt a predetermined secondary structure. For example, the peptide may be designed to adopt a 0-hairpin secondary structure, as previously described. The predetermined secondary structure may comprise a structure preselected from at least one of a 0-sheet, an a-helix, and a random coil. In exemplary embodiments, the hydrophobic amino acid residues (for example, quantity, placement, and / or structure of the hydrophobic amino acid residues) may be selected to self-assemble the peptide into a polymer having a majority of 0-sheet structures. In particular embodiments, the hydrophobic amino acid residues may be selected to control stiffness of the hydrogel. For example, an amount and type of hydrophobic amino acid residues may be selected to control stiffness of the hydrogel.
[0241] In some embodiments, an external stimulus such as temperature, change in pH, light, and applied sound wave may be used to control and promote preferential secondary structure formation of the self-assembling peptide. Control of the secondary structure formation may enhance biological, biophysical, and chemical therapeutic functions of the peptide. For example, higher cell membrane penetration of self-assembling peptides may be achieved by exposing 0-hairpin peptides to high pH (for example, at least pH 9) or high temperatures (for example, at least 125 °C) or low temperatures (for example, 4 °C or lower). The result is hydrogels with a peptide secondary structure having a majority 0-sheet or a-helix formation.
[0242] The peptide may be designed to give the preparation shear-thinning properties. In particular, the peptide may be designed to be injectable. For instance, the peptide may be designed to be an injectable solid or gel by employing shear-thinning kinetics. The preparation, in the form of a solid or gel prior to application, may be configured to shear-thin to a flowable state under an effective shearDocket No. G2093-7013WO
[0243] stress applied during administration by the delivery device. In some exemplary embodiments, the solid or gel may shear-thin to a flowable state during injection or topical application with a syringe. Other modes of administration may be employed. The solid or gel may shear-thin to a flowable state during endoscopic administration. The solid or gel may be configured to shear-thin to flow through an anatomical lumen, for example, an artery, vein, gastrointestinal tract, bronchus, renal tube, genital tract, etc. In some embodiments, the shear thinning properties may be employed during transluminal procedures.
[0244] The shear-thinning kinetics of the hydrogel may be engineered by altering the net charge of the peptides. In some embodiments, the net charge may be altered by controlling one or more of the presence or absence of cationic particles or peptides, the presence or absence of anionic particles or peptides, buffers, salts, peptide concentration, peptide purity, and the presence or absence of peptide counterions. In particular, shear-thinning may be controlled by altering the peptide purity to achieve the desired shear-thinning kinetics. The net charge of the peptide may be positive. The net charge of the peptide may be negative.
[0245] Shear-thinning may be induced by mechanical agitation to the hydrogel or environmental stimulus. Mechanical agitation may be induced, for example, through delivery or sonication mixing. Environmental stimulus may be induced by addition of heat, light, ionic agents, chelator agents, buffers, or proteins, or altering pH level.
[0246] Thus, the preparations may be substantially flowable. The methods may include dispensing the preparation through a cannula or needle. The methods may include conformally filling wound beds of any size and shape. The peptide hydrogels may have shear-thinning mechanical properties. The shear-thinning mechanical properties may allow the gel network to be disrupted and become a fluid during administration, for example, during injection from a needle or administration with a spray nozzle. When the applied stress ceases, the gel network may reform and the elastic modulus may be restored within a predetermined period of time, for example, several minutes. The shearthinning peptide hydrogels may be employed to protect cells from damage during injection, showing an improved viability over direct injection in saline or media. The shear-thinning hydrogel may display non-Newtonian fluid flow, which may allow for effective mixing of excipients, for example, within minutes to a couple hours. In some embodiments, dyes, small molecules, and large molecules may be substantially homogeneously dispersed within the hydrogel in less than 120 minutes, for example, between 30-120 minutes.
[0247] The peptide may self-assemble into a translucent hydrogel. In some embodiments, the peptide may self-assemble into a substantially transparent hydrogel. The peptide may self-assembleDocket No. G2093-7013WO
[0248] into a semi-transparent hydrogel. The hydrogel may have at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 99%, or about 100% light transmittance. The hydrogel may be colorless. The light transmittance and color of the hydrogel may be engineered by tuning the sequence of the peptide and / or the composition of the preparation or solution. As shown in the graphs of FIG. 8, transparency of the peptide hydrogels may be quantified by absorbance measurements. The exemplary peptide hydrogels measured in FIG. 8 are substantially transparent.
[0249] In some embodiments, the preparation may include a dye. The dye may be a food-grade dye or a pharmaceutical-grade dye. The dye may be cytocompatible. The dye may be biocompatible. In general, the dye may assist the user or healthcare provider to view the hydrogel after application. The preparation may include an effective amount of the dye to provide a desired opacity of the hydrogel. The hydrogel may comprise an effective amount of the dye to have a light transmittance of less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, or less than about 10%. The hydrogel may be substantially opaque when including the dye. The hydrogel may be semi-transparent when including the dye. One exemplary dye is methylene blue.
[0250] The peptide may self-assemble into a substantially ionically-crosslinked hydrogel. “Ionic crosslinkage” may refer to ionic bonds between peptides to form secondary structure proteins and / or between secondaiy structure proteins that form the hydrogel tertiary structure. The shear-thinning properties of the hydrogel may be enabled by physical crosslinks, allowing ionic bonds to be broken and reformed. In accordance with certain embodiments, the hydrogel is formed of a majority of ionic crosslinks. For example, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, more than 95%, more than 99%, or substantially all of the physical crosslinks of the formed hydrogel may be ionic in nature.
[0251] The preparation and / or assembled hydrogel may be designed to have a substantially physiological pH level. The preparation or hydrogel may have a pH level of between about 4.0 and 9.0. In some embodiments, the preparation or hydrogel may have a pH level of between about 7.0 and 8.0. The preparation or hydrogel may have a pH level of between about 7.3 and 7.5.
[0252] The substantially physiological pH may allow administration of the preparation at the time of gelation. In some embodiments, the hydrogel may be prepared at a point of care. The methods may comprise mixing the preparation with a buffer configured to induce self-assembly, optionally agitating the mixture, and administering the preparation or hydrogel at a point of care. The administration may be topical or parenteral, as described in more detail below.Docket No. G2093-7013WO
[0253] In some embodiments, the methods may comprise administering the preparation as a liquid. The methods may comprise administering the preparation as a gel. The methods may comprise administering the preparation as a solid or semi-solid.
[0254] In some embodiments, the preparation may be designed to self-assemble after a lapsed period of time. For example, the preparation may be designed such that the peptide is configured to begin self-assembly in less than about 5 minutes, in less than about 3 minutes, in less than about 2 minutes, in less than about 30 seconds, in less than about 10 seconds, or in less than about 3 seconds. In certain embodiments, the preparation may be designed such that the peptide is configured to selfassemble, i.e. be substantially self-assembled, within about 60 minutes, within about 30 minutes, within about 15 minutes, within about 10 minutes, within about 5 minutes, within about 3 minutes, within about 2 minutes, within about 30 seconds, within about 10 seconds, within about 5 seconds, or within about 3 seconds. The preparation may have a composition configured to control timing of self-assembly. For example, the preparation may have a composition configured for timed release of ionic agents or pH-altering agents. In certain embodiments, the sequence or structure of the peptide may be designed to control self-assembly of the peptide.
[0255] In some embodiments, the methods may comprise combining the preparation with a buffer. The “buffer” may refer to an agent configured to induce gelation, prior to, subsequently to, or concurrently with administration of the preparation to the subject. Thus, in some embodiments, the preparation may comprise a buffer. For example, the preparation may comprise or be combined with up to about 1000 mM of the buffer. The buffer may comprise an effective amount of ionic salts and a buffering agent, for example, to induce gelation and / or provide desired properties. For example, the buffer may be formulated to control or maintain pH of the preparation.
[0256] In particular embodiments, the buffer may have an effective amount of ionic salts to control stiffness of the hydrogel. The “ionic salt” may refer to a compound which dissociates into ions in solution. The buffer may comprise between about 5 mM and 400 mM ionic salts. For example, the buffer may comprise between about 5 mM and 200 mM ionic salts, between about 50 mM and 400 mM ionic salts, between about 50 mM and 200 mM ionic salts, or between about 50 mM and 100 mM ionic salts. The ionic salt may be one that dissociates into at least one of sodium, potassium, calcium, magnesium, iron, ammonium, pyridium, quaternary ammonium, chloride, citrate, acetate, and sulfate ions. The ionic salts may comprise sodium chloride, ammonium chloride, magnesium chloride, potassium chloride, calcium chloride, ammonium sulfate, magnesium sulfate, sodium sulfate, potassium sulfate, calcium sulfate, sodium bicarbonate, and combinations thereof.Docket No. G2093-7013WO
[0257] In exemplary embodiments, the buffer may comprise between about 1 mM and about 200 mM sodium chloride. For example, the buffer may comprise between about 10 mM and about 150 mM sodium chloride, for example between about 50 mM and about 100 mM sodium chloride.
[0258] The buffer may comprise counterions. The buffer may have an effective amount of counterions to render the hydrogel substantially electrically neutral. The buffer may have an effective amount of counterions to induce self-assembly of the peptide. The concentration of counterions may be dependent on the composition of the peptide preparation. Additionally, the charge of the counterions may be dependent on the charge of the peptide preparation. Thus, the counterions may be anions or cations. In general, the counterions may be cytocompatible. In certain embodiments, the counterions may be biocompatible. For instance, the counterions may comprise acetate or chloride. In other embodiments, the biocompatible solution may be substantially free of chloride counterions.
[0259] The buffer may comprise from about 1 mM to about 150 mM of a biological buffering agent. For example, the buffer may comprise from about ImM to about 100 mM of a biological buffering agent, from about 1 mM to about 40 mM of a biological buffering agent, or from about 10 mM to about 20 mM of a biological buffering agent. The biological buffering agent may be selected from Bis-tris propane (BTP), 4-(2-hydroxyethyl)-l -piperazineethanesulfonic acid (HEPES), Dulbecco's Modified Eagle Medium (DMEM), tris(hydroxymethyl)aminomethane (TRIS), 2-(N-Morpholino)ethanesulfonic acid hemisodium salt, 4-Morpholineethanesulfonic acid hemisodium salt (MES), 3-(N morpholino)propanesulfonic acid (MOPS), and 3-(N-morpholino)propanesulfonic acid (MOBS), Tricine, Bicine, (tris(hydroxymethyl)methylamino)propanesulfonic acid (TAPS), N-(2-Acetamido)-2-aminoethanesulfonic acid (ACES), P-Hydroxy-4-morpholinepropanesulfonic acid, 3-Morpholino-2-hydroxy propanesulfonic acid (MOPSO), (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid) (BES) and combinations thereof. Other biological buffering agents are within the scope of the disclosure.
[0260] In exemplary embodiments, the buffer may comprise from about 1 mM to about 150 mM of BTP. The buffer may comprise from about 10 mM to about 100 mM BTP, for example, from about 10 mM to about 50 mM BTP, from about 10 mM to about 40 mM, from about 20 mM to about 40 mM, or from about 20 mM to about 40 mM.
[0261] The buffer may additionally comprise at least one of water, an acid, and a base. The acid and / or base may be added in an amount effective to control pH of the buffer to be a substantially physiological pH. In other embodiments, the buffer may be acidic, alkali, or substantially neutral. The buffer may be selected to control pH of the hydrogel and maintain a desired pH at the target site. For example, to control pH of the hydrogel to be a substantially physiological pH at the target site.Docket No. G2093-7013WO
[0262] Thus, the properties of the buffer may be selected based on the target site. The buffer may have additional properties as selected, for example, net charge, presence or absence of additional proteins, etc. The buffer may additionally comprise one or more minerals.
[0263] The preparation may further comprise an effective amount of a mineral clay. The preparation may comprise between about 0.1% w / v to about 20% w / v of the mineral clay. For example, the preparation may comprise 0.75% w / v, 1.5% w / v, 2% w / v, 3% w / v, 4% w / v, 8% w / v, 10% w / v, or 20% w / v of the mineral clay. The amount of the mineral clay may be effective to provide desired rheological properties for the target site of application. The amount of the mineral clay may be effective to form a film. The mineral clay may be natural or synthetic. The mineral clay may comprise at least one of laponite and montmorillonite. In some embodiments, the preparation may comprise from a 1 : 1 to 1 :2 ratio (w / v) of the peptide to mineral clay. For example, the ratio of peptide to mineral clay in the preparation may be 1:1, 3:4, 3:8, or 1 :2 (w / v).
[0264] In certain embodiments, the preparation may be formulated for a combination treatment. The preparation may include at least one active agent configured to provide a combination treatment. In some embodiments, the preparation may exhibit synergistic results with combination of the active agent. The active agent may be, for example, an antibacterial composition, an antiviral composition, an antifungal composition, an anti-tumor composition, an anti-inflammatory composition, a hemostat, a cell culture media, a cell culture serum, an anti-odor composition, an analgesic, local anesthetic, a pain-relief composition, or a biological material.
[0265] In some embodiments, the preparation and / or hydrogel may be designed to be thermally stable between -20 °C and 150 °C, between -20 °C and 125 °C, between -20 °C and 100 °C, between 2 °C and 125 °C, and between 37 °C and 125 °C. As disclosed herein, “thermal stability” refers to the ability to withstand temperature treatment without substantial degradation, loss of biological activity, or loss of chemical activity. The graphs of FIGS. 7A-7B show peptide aggregation as measured by static light scattering (SLS) at 266 nm of exemplary peptides as a function of temperature. The exemplary peptides include arginine, lysine, valine, threonine, and proline residues. As shown in the graphs of FIGS. 7A-7B, the peptide hydrogels and peptides are thermostable as a function of temperature.
[0266] In certain embodiments, the preparation and / or peptide may be mechanically stable. For instance, the preparation may be shear thinned or sonicated. The preparation may be sonicated without substantial degradation, loss of biological or chemical activity. The preparation may be shear thinned without substantial degradation, loss of biological or chemical activity.Docket No. G2093-7013WO
[0267] In certain embodiments, the preparation and / or peptide may be sterile or sterilized. For instance, in some embodiments, the hydrogel may be sterile or sterilized. The preparation and / or peptide may be sterilized by autoclave sterilization. During autoclave sterilization, the preparation and / or peptide may be heated to a temperature of between 120 °C to 150 °C, for example, up to 125 °C, up to 135 °C, or up to 150 °C. The preparation and / or peptide may be held at autoclave temperature for at least about 2 minutes, for example, between about 2-20 minutes or between about 10-160 minutes. The autoclave sterilization may be sufficient to sterilize at least about 90%, 95%, 99%, 99.9%, 99.99%, 99.999%, or 100% of any pathogenic microorganism. The preparation and / or peptide may remain stable during and after autoclave sterilization. For instance, the preparation and / or peptide may remain physically, chemically, biologically, and / or functionally stable after autoclave sterilization.
[0268] In certain embodiments, the preparation and / or peptide may be pasteurized. During pasteurization, the preparation and / or peptide may be heated to a temperature of between 50 °C to 100 °C, for example, up to 60 °C, up to 70 °C, or up to 100 °C. The preparation and / or peptide may be held at pasteurization temperature for at least about 15 seconds, for example, between about 1-30 minutes or between about 3-15 minutes. The pasteurization may be sufficient to sterilize at least about 90%, 95%, 99%, 99.9%, 99.99%, or 99.999% of any pathogenic microorganism.
[0269] In certain embodiments, the preparation may be sterilized by ultra-high temperature (UHT) or high temperature / short time (HTST) sterilization. During UHT or HTST sterilization, the preparation and / or peptide may be heated to a temperature of between 100 °C to 150 °C, for example, up to 130 °C, up to 140 °C, or up to 150 °C. The preparation and / or peptide may be held at UHT or HTST temperature for at least about 15 seconds, for example, between about less than 1 minute to about 6 minutes, for example, between about 2-4 minutes. The UHT or HTST sterilization may be sufficient to sterilize at least about 90%, 95%, 99%, 99.9%, 99.99%, or 99.999% of any pathogenic microorganism.
[0270] In certain embodiments, the sterilization or pasteurization may be terminal. Terminal sterilization or pasteurization may refer to treatment of the preparation in a sealed end -use package.
[0271] The preparation and / or peptide may be stable during and after heat treatment. As disclosed herein, stability during and after heat treatment, for example, autoclave sterilization, may refer to reduced or inhibited degradation, biological activity, and chemical activity. For instance, the preparation and / or peptide may be heat treated without degradation, a loss of biological activity, or a loss of chemical activity. Biological activity may refer to any bioactive property of the peptide disclosed herein. In some embodiments, biological activity may refer to antimicrobial activity.Docket No. G2093-7013WO
[0272] Chemical activity may refer to any chemical or physicochemical property of the peptide disclosed herein. In some embodiments, chemical activity may refer to the ability to self-assemble and or shear-thinning properties of the peptide disclosed herein. Thus, the preparation and / or peptide may be heat treated without loss of antimicrobial activity, self-assembly, or shear-thinning properties. In certain embodiments, heat treatment may enhance one or more biological activity or chemical activity of the peptide and / or preparation. For example, heat treatment may enhance antimicrobial activity, self-assembly, or shear-thinning properties of the peptide or preparation.
[0273] The preparation may be sterile. For example, the preparation may remain substantially sterile without the addition of a preservative.
[0274] The preparation may have a predetermined shelf-life. “Shelf-life” may refer to the length of time for which the preparation may remain stable and / or maintain efficacy after storage under the given conditions. The preparation and / or hydrogel may have a shelf-life of at least about 1 year at a temperature between -20 °C and 150 °C. For instance, the preparation and / or hydrogel may have a shelf-life of at least about 1 year at room temperature (between about 20 °C and 25 °C). The preparation and / or hydrogel may have a shelf-life of at least about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years at room temperature. The preparation and / or hydrogel may be stable at a pressure of up to about 25 psi, for example, up to about 15 psi.
[0275] The peptide may be capable of self-assembly at a temperature between 2 °C and 40 °C. For example, the peptide may be capable of self-assembly in an environment having a temperature between 2 °C and 20 °C, between 20 °C and 25 °C, or between 36 °C and 40 °C.
[0276] The peptide may be substantially unassembled at temperatures higher than 40 °C. For instance, the peptide preparation may be substantially liquid at temperatures between 40 °C and 150 °C. The peptide preparation may be substantially liquid and thermally stable at temperatures between 40 °C and 125 °C or up to 150 °C. Temperature may be controlled for handling of the preparation. For example, the preparation may be heated to a temperature greater than 40 °C for packaging, handling, and / or administration in a liquid state.
[0277] The preparation may be formulated for a desired route of administration. For example, the preparation may be formulated for topical or parenteral administration. In particular, the preparation may be engineered to have a viscosity appropriate for topical administration or parenteral administration. Preparations for topical administration may be formulated to withstand environmental and mechanical stressors at the site of administration or target site. Preparations for parenteral administration may be formulated to reduce migration from the site of administration or target site. In other embodiments, preparations for parenteral administration may be formulated to triggerDocket No. G2093-7013WO
[0278] migration from a site of administration to the target site. The preparation may be formulated for administration by a particular delivery device. For example, the preparation may be formulated for administration by spray, dropper, or syringe. The preparation may be formulated for administration by injection or catheter.
[0279] Table 1 includes the analytical characterization of three exemplary peptide preparation samples. The exemplary peptides have arginine-rich sequences comprising two lysine amino acid residues. The values were detected by conventional detection methods. Components indicated “N.D.” were below detection limit. Peptide purification, residual solvents, peptide content, and water content, may be selected to control antimicrobial activity and cell membrane disruption potential of the hydrogels.
[0280] Table 1: Exemplary Peptide Preparations
[0281] Residual Solvents
[0282] N, N- Net Triethyl Dimethyl Ethyl
[0283] Purity Acetate TFA Water Peptide Isopropanol Methanol Acetonitrile amine formamide ether
[0284] # (%) (%) (%) (%) (%) (PPm) (PPm) (PPm) (PPm) (PPm) (PPm) DCM DIC MPS 1 97.9 19.3 N.D. 6.5 78.6 81 28 17 N.D. N.D. N.D. N.D. N.D. N.D.
[0285] 2 93.7 16.3 N.D. 7.1 79.3 63 28 18 56 116 N.D. N.D. N.D. N.D.
[0286]
[0287] 3 96.0 16.9 N.D. 6.2 76.1 N.D. N.D. 4.6 2.9 N.D. N.D. N.D. N.D. N.D.
[0288] The purified preparation and hydrogel may be substantially endotoxin free without addition of a preservative or sterilization, as shown in Table 2. Thus, in some embodiments, the peptide preparation and / or peptide may be substantially free of a preservative.
[0289] Table 2: Endotoxin Levels of Different Compositions
[0290] OD at 410nm Endotoxin level (EU / mL) Endotoxin free water -0.000333333 -0.016148109
[0291] RO water 3.436666667 1.267607913
[0292] Tap water 3.463666667 1.2776927
[0293] Buffer solution -0.056 -0.036940201
[0294] Peptide 0.006 -0.013782542
[0295]
[0296] Peptide hydrogel 0.015 -0.010420946
[0297] The self-assembling peptide hydrogel
[0298] The preparations disclosed herein may be provided to self-assemble into a hydrogel having preselected properties. The polymeric hydrogel may have a substantially physiological pH. InDocket No. G2093-7013WO
[0299] general, the polymeric hydrogel may have a pH of between 4.0 and 9.0, for example, between 7.0 and 8.0, between 7.2 and 7.8, or between 7.3 and 7.5.
[0300] The polymeric hydrogel may be substantially transparent. For example, the polymeric hydrogel may be substantially free of turbidity, for example, visible turbidity. Visible turbidity may be determined by macroscopic and microscopic optical imaging. The polymeric hydrogel may be substantially free of peptide aggregates (peptide clusters), for example, visible peptide aggregates. Visible peptide aggregates may be determined by static light scattering (SLS) and UV-VIS testing. “Transparency” may refer to the hydrogel’s ability to pass visible light. The substantially transparent hydrogel may have UV-VIS light absorbance of between about 0.1 to 3.0 ±1.5 at a wavelength of between about 205 nm to about 300 nm.
[0301] The assembled polymeric hydrogel may have a nano-porous structure. The polymeric hydrogel may be hydrated or substantially saturated. In some embodiments, the hydrogel may have between 90% w / v and 99.9% w / v aqueous solution, for example, between 92% w / v and 99.9% w / v or between 94% w / v and 99.9% w / v. The nano-porous structure may be selected to be impermeable to a target microorganism. Thus, the hydrogel may be used to encapsulate a target microorganism or to maintain the target site free from the target microorganism. The nano-porous structure may be selected to allow gaseous exchange at the target site. The polymeric hydrogel may have a nano-porous structure having a pore size of between 1 nm and 1000 nm, as selected (e.g., based on a target microorganism, target cell, or desired functionality). The polymeric hydrogel may have a fibril width of between 1 nm and 100 nm, as selected.
[0302] In particular, the peptide sequence and structure may include peptide functional groups that form nanofibers, which further self-assemble to form macromolecular structures (FIGS. 1A-1B). The peptide hydrogels may assemble into an extracellular scaffolding matrix that is similar to native fibrillar collagen (FIGS. 1A-1B). Schematics of gel matrix self-assembly and an exemplary nanostructure are shown in FIGS. 1A-1B. As shown in FIG. 1A, single peptide nanofibers selfassemble into a gel when ionic buffer is added. FIG. 1 A includes a TEM image demonstrating that the nanostructure and pore size of the peptide gel look similar to native ECM (collagen). FIG. IB includes a schematic drawing of an intra-operative mixing device for mixing a cell suspension with peptide gel matrix. A schematic SEM image in FIG. IB of the cell-laden matrix demonstrates the exemplary concept of cells in matrix.
[0303] The peptide may be engineered by design to self-assemble into a hydrogel which is substantially biocompatible. The peptide may be engineered by design to self-assemble into a hydrogel that is cell friendly. In certain embodiments, the cell-friendly polymeric hydrogel may beDocket No. G2093-7013WO
[0304] non-inflammatory, and / or non-toxic. The cell-friendly polymeric hydrogel may be substantially biodegradable. The peptide may be engineered by design to be substantially antimicrobial, antiviral, and / or antifungal.
[0305] The peptides and / or peptide functional groups may be synthetic, e.g., produced synthetically. Thus, the peptides may provide ease of manufacturing, scale-up, and quality control. In general, the peptides may be manufactured without the use of plant or animal expression systems. The peptides may be substantially free of naturally occurring endotoxins and disease-transmitting pathogens. In addition, the peptide sequence and functional groups may be tuned, allowing a versatility in control and design of the assembled hydrogel, including with respect to physical and chemical properties, such as biodegradation, mechanical properties, and biological activity.
[0306] The peptide may have a functional group engineered for a target indication. For instance, the peptide may have a bioactive functional group. The target indication may be tissue engineering of a target tissue. The target indication may include, for example, cell culture, cell delivery, wound healing, and / or treatment of biofilm. Thus, the peptide may be engineered by design to self-assemble into a hydrogel which is substantially biocompatible. The peptide functional group may have between about 4 and about 40 amino acid residues, e.g., between about 3 and about 30 amino acid residues. For example, the peptide functional group may have between about 3 and about 20 amino acid residues. The peptide functional group may have a sequence selected from RGD (SEQ ID NO: 24), IKVAV (SEQ ID NO: 25), YIGSR (SEQ ID NO: 26), LKKTETQ (SEQ ID NO: 27).
[0307] SNKPGVL (SEQ ID NO: 28), PKPQQFFGLM (SEQ ID NO: 29), GKLTWQELYQLKYKGI (SEQ ID NO: 30), and GGG (SEQ ID NO: 31).
[0308] In some embodiments, the peptide may include a modification selected from a linker and a spacer. Peptide “linkers” may generally refer to short amino acid sequences included to link multiple domains of the peptide. Peptide “spacers” may generally refer to amino acid sequences positioned to link and control the spatial relationship of the multiple domains of the assembled protein. The linker or spacer may be hydrophobic or hydrophilic. The linker or spacer may be rigid or flexible.
[0309] Exemplary spacers include aminohexanoic acid (Ahx) (hydrophobic) and poly (ethylene) glycol (PEG) (hydrophilic). Glycine rich spacers are generally flexible.
[0310] Exemplary bioactive functional groups include laminin, bone marrow homing, collagen (e.g., I, II. and VI), bone marrow purification, and RGD / fibronectin types. Exemplary bioactive functional groups include VEGF, Substance P, Thymosin Beta, Cardiac Homing Peptide, Bone Marrow Homing Peptide, Osteopontin, and Oste genic peptide. Exemplary bioactive functional groups include those in Tables 3-5 below.Docket No. G2093-7013WO
[0311] Table 3: Exemplary Bioactive Functional Groups
[0312] ECM Motif ECM Type
[0313] -GGPDSGR (SEQ ID NO: 32) Laminin
[0314] -GGSDPGYIGSR (SEQ ID NO: 33) Laminin
[0315] -GGSKPPGTSS (SEQ ID NO: 34) Bone marrow homing
[0316] -GGDGEA (SEQ ID NO: 35) Collagen 11
[0317] -GGPFSSTKT (SEQ ID NO: 36) Bone marrow homing
[0318] -GGFLGFPT (SEQ ID NO: 37) Bone marrow purification
[0319] -GGRGDS (SEQ ID NO: 38) RGD / fibronectin
[0320] -GGIKVAV (SEQ ID NO: 39) Laminin
[0321] -GGFPDERGVEGPGP (SEQ ID NO: 40) Collagen I
[0322]
[0323] -GGPRGDSGYRGDSF (SEQ ID NO: 41) Collagen VI
[0324] Table 4: Exemplary Bioactive Functional Groups
[0325] Protein / Peptide Bioactive Motif
[0326] VEGF GKLTWQELYQLKYKGI (SEQ ID NO: 42) Substance P RPKPQQFFGLM (SEQ ID NO: 43) Thymosin Beta SNKPG (SEQ ID NO: 44)
[0327] Thymosin Beta LKKTETQG (SEQ ID NO: 45)
[0328] Cardiac Homing Peptide CSTMLKAC (SEQ ID NO: 46)
[0329] Bone Marrow Homing Peptide GCPFSSTKTE (SEQ ID NO: 47) Osteopontin TLEGTKKGHKLHLDY (SEQ ID NO: 48)
[0330]
[0331] Osteogenic Peptide ALKRQGRTLYGFGG (SEQ ID NO: 49)
[0332] Table 5: Exemplary Bioactive Functional Groups
[0333] Peptide name Sequence Source
[0334] RGD XRGDX (SEQ ID NO: 50) Fibronectin,
[0335] osteopontin, BSP and others pRGD / bsp-RGD CGGNGEPRGDTYRAY (SEQ ID NO: 51) BSP
[0336] hBS?278-293 YESENGEPRGDNYRAY (SEQ ID NO: 52) BSP
[0337] PHSRN PHSRN (SEQ ID NO: 53) Fibronectin
[0338] F105 YKRSRYT (SEQ ID NO: 54) FGF-2
[0339] F119 KRTGQYKLGSKTGPGQK (SEQ ID NO: 55) FGF-2
[0340] F36 PDGRVD (SEQ ID NO: 56) FGF-2
[0341] F77 KEDGRLL (SEQ ID NO: 57) FGF-2
[0342] GFOGER GGYGGGPC(GPP)5GFOGER Collagen type I (GPP)SGPC (SEQ ID NO: 58)
[0343] DGEA DGEA (SEQ ID NO: 59) Collagen type I P15 GTPGPQGIAGQRGVV (SEQ ID NO: 60) Collagen type I
[0344]
[0345] AC-100 ERGDNDISPFSGDGQ (SEQ ID NO: 61) MEPEDocket No. G2093-7013WO
[0346] ODP DVDVPDGRGDSLAYG (SEQ ID NO: 62) Osteopontin (osteopontin- derived peptide)
[0347] RRETAWA RRETAWA (SEQ ID NO: 63) Identified by phage display
[0348] YIGSR YIGSR (SEQ ID NO: 64) Laminin
[0349] IKVAV IKVAV (SEQ ID NO: 65) Laminin
[0350] Ln2-P3 DLTIDDSYWYRI (SEQ ID NO: 66) Laminin
[0351] KRSR KRSR (SEQ ID NO: 67) BSP, fibronectin,
[0352] osteopontin and others
[0353] Consensus FHRRIKA (SEQ ID NO: 68) BSP
[0354] heparin binding
[0355] domain
[0356] HBD peptide RKKNPNCRRH (SEQ ID NO: 69) BMP-4
[0357] BMP-2-derived NSVNSKIPKACCVPTELSAI (SEQ ID NO: BMP-2
[0358] peptide 70)
[0359] BMP-2-derived KIPKASSVPTELSAISTLYL (SEQ ID NO: 71) BMP-2
[0360] peptide
[0361] P24 S[PO4]KIPKASSVPTELSAIST LYLDDD (SEQ BMP-2
[0362] ID NO: 72)
[0363] pBMP-9 / SpBMP- CGGKVGKA(CC / SS)VPTKL SPISVLYK BMP-9
[0364] 9 (SEQ ID NO: 73)
[0365] BMP-9-derived RKVGKASSVPTKLSPI SILYK (SEQ ID NO: BMP-9
[0366] peptide 74)
[0367] BMP-7 -derived RTVPKPSSAPTQLNAI STLYF (SEQ ID NO: BMP-7
[0368] peptide 75)
[0369] BFP-1 GQGFSYPYKAVFSTQ (SEQ ID NO: 76) BMP-7
[0370] OPD DWIVA (SEQ ID NO: 77) BMP-2 (osteopromotive- domain)
[0371] CBM GLRSKSKKFRRPDIQYPDA TDEDITSHM Osteopontin
[0372] (SEQ ID NO: 78)
[0373] BCSP™-1 NGLPGPIGP (SEQ ID NO: 79) Collagen type I OGP (osteogenic ALKRQGRTLYGFGG (SEQ ID NO: 80) Naturally occurring growth peptide)
[0374] OGP10-14 YGFGG (SEQ ID NO: 81) OGP
[0375] PTHI-34 SVSEIQLMHNLGKHLNSME Parathyroid RVEWLRKKLQDVHNF (SEQ ID NO: 82) hormone
[0376] CB NGVFKYRRRYYLYKHAYF YPHLKRFPVQ BSP
[0377] (SEQ ID NO: 83)
[0378] CTC peptide IAGVGGEKSGGF (SEQ ID NO: 84) Collagen-IIIa Substance-P RPKPQQFFGLM (SEQ ID NO: 85) Naturally occurring Endothelin-1 CSCSSLMDKECVYFCHLD IIW (SEQ ID Naturally occurring
[0379]
[0380] NO: 86)Docket No. G2093-7013WO
[0381] QK KLTWQELYQLKYKGI (SEQ ID NO: 87) VEGF
[0382] PBA2-1C (CVRKIEIVRKK)2-Ahx-Ahx-Ahx- PDGF RKRKLERIAR (SEQ ID NO: 88)
[0383] Exendin 4 HGEGTFTSDLS KQMEEEA VR Glucagon-like LFIEWLKNGGPSSGAPPPS (SEQ ID NO: 89) peptide
[0384] OPD SVVYGLR (SEQ ID NO: 90) Osteopontin (osteopontin- derived peptide)
[0385] SPARC 113 TLEGTKKGHKLHLDY (SEQ ID NO: 91) Osteonectin
[0386] SPARC 118 KKGHK (SEQ ID NO: 92) Osteonectin
[0387] TP508 AGYKPDEGKRGDACEGDS GGPFV (SEQ Thrombin
[0388] ID NO: 93)
[0389] RoY YPHIDSLGHWRR (SEQ ID NO: 94) Designed
[0390] LL-37 LLGDFFRKS KEKIGKEFKRI hCAP18
[0391]
[0392] VQRIKDFLRNLVPRTES (SEQ ID NO: 95)
[0393] The peptide may have a functional group engineered to control or alter charge or pH of the peptide or preparation. A pre-selected charge or pH may provide bioactive properties. In some embodiments, a pre-selected charge or pH may provide antimicrobial, antifungal, and / or antiviral properties. In some embodiments, a pre-selected charge or pH may allow the preparation to be administered to a compatible target site.
[0394] The peptide may have an antimicrobial functional group. The antimicrobial functional group may include a conserved sequence of antimicrobial residues. In other embodiments, the antimicrobial functional group may overlap or partially overlap with the self-assembling functional group. In at least one embodiment, the peptide may have alternating or substantially alternating antimicrobial and self- assembling residues.
[0395] The peptide may have an antifungal functional group. The antifungal functional group may include a conserved sequence of antifungal residues. In other embodiments, the antifungal functional group may overlap or partially overlap with the self-assembling functional group. In at least one embodiment, the peptide may have alternating or substantially alternating antifungal and selfassembling residues.
[0396] The peptide may have an antiviral functional group. The antiviral functional group may include a conserved sequence of antiviral residues. In other embodiments, the antiviral functional group may overlap or partially overlap with the self-assembling functional group. In at least one embodiment, the peptide may have alternating or substantially alternating antiviral and selfassembling residues.Docket No. G2093-7013WO
[0397] The self-assembled hydrogel may be designed to have cell protective properties at the target site. In particular, the self-assembled hydrogel may be designed to be protective against foreign microorganisms, e.g., pathogenic microorganisms. The self-assembled hydrogel may be designed to be protective against fungal organisms. The self-assembled hydrogel may be designed to be protective against immune attack from environmental immune cells. The antimicrobial, antiviral, antifungal, and / or protective properties of the hydrogel may not substantially affect the viability, growth, or function of cells at the target site.
[0398] The protective properties of the hydrogel may be engineered by altering the net charge of the peptides. In some embodiments, the net charge may be altered by controlling one or more of the presence or absence of cationic particles or peptides, the presence or absence of anionic particles or peptides, buffers, salts, peptide concentration, peptide purity, and the presence or absence of peptide counterions. The peptide may be engineered to have positively charged, negatively charged, hydrophobic, or hydrophilic amino acid residues. In an exemplary embodiment, the peptide may provide antimicrobial, antiviral, and / or antifungal properties by inclusion amino acids which are positively charged at a substantially neutral pH level. Such amino acids may include, for example, arginine, lysine, tryptophan, and histidine.
[0399] The peptide hydrogel may additionally exhibit antimicrobial properties. In general, the antimicrobial properties may be provided by including an antimicrobial functional group. In some embodiments, the antimicrobial functional group may include a cation-rich peptide sequence. In exemplary embodiments, the antimicrobial functional group may include varying ratios of lysine (K) and arginine (R) (FIG. 4). The antimicrobial peptide hydrogel may provide antimicrobial effects against gram-positive and negative bacteria, including, for example, E. coll (FIG. 4), S. aureus, and P. aeruginosa. FIG. 4 is a graph showing antimicrobial activity (as percent non- viable E. coli remaining after 24 hours of administration) of varying concentrations of peptides having 8 arginine residues (PEP8R), 6 arginine residues (PEP6R), 4 arginine residues (PEP4R), and 2 arginine residues (PEP2R).
[0400] The peptide hydrogels may exhibit broad-spectrum antimicrobial activity. In accordance with certain embodiments, the peptide hydrogels may reduce bioburden in vivo in partial thickness wounds inoculated with methicillin-resistant S. aureus (MRSA) (FIG. 5). FIG. 5 shows preliminary data demonstrating antimicrobial benefits of treating bioluminescent MRSA (US300) with peptide gels. Images (A) and (B) show wells plated with 100 pl of gel and 100 pl of US300 (1x10sCFU / ml) demonstrating the antimicrobial activity of peptide gels compared to controls at 1 hour and 3 hours (n=3). Image (C) shows mice with partial thickness burns inoculated with 50 pl of 10sCFU / mlDocket No. G2093-7013WO
[0401] US300 and treated with peptide gels. As shown in image (C), the mice exhibit reduced bioburden at 3 hours after administration.
[0402] In particular, the peptide hydrogel may exhibit antimicrobial properties against foreign and / or pathogenic microorganisms, and be compatible with the administered cells. For example, such peptide hydrogels may be compatible with mammalian erythrocytes and macrophages. In one exemplary experiment, when bacteria and mammalian cells were seeded simultaneously onto the peptide hydrogels disclosed herein, the bacteria were killed while the mammalian cells remained >90% viable after 24 hours and could continue to proliferate.
[0403] The peptide hydrogels can mediate cell attachment (FIG. 6) to support the viability and function of MSCs, as well as serve as a scaffolding matrix for infiltration of endogenous cells during the wound healing process. FIG. 6 includes images demonstrating selective toxicity against pathogens. In particular, FIG. 6 shows live cells (green) and dead cells (red) on an assay of cocultured MRSA and C3H10tl / 2 mesenchymal stem cells (MSCs) on the peptide hydrogels. As shown in the right image of FIG. 6, MRSA is killed while mammalian cells remain healthy. Higher magnification shows C3H10tl / 2 cells are able to adhere and spread on the hydrogel.
[0404] In some embodiments, the peptides may include functional groups to enhance or promote biological activity compatible or synergizing with MSC function. For example, in certain embodiments, the peptide sequence may contain a functional group that mimics fibronectin and promotes adhesion and proliferation of human MSCs to a greater extent than other ECM ligands. In certain embodiments, the peptide sequence may contain a functional group comprising a neuropeptide to promote diabetic wound healing by suppressing inflammation and inducing angiogenesis. In certain embodiments, the peptide sequence may contain a functional group comprising a neuropeptide to induce the proliferation and migration of MSCs, as well as enhance the immunomodulatory function of MSCs. In certain embodiments, the peptide sequence may contain a functional group to improve wound healing by increasing angiogenesis and inducing MSC proliferation and migration. In certain embodiments, the peptide sequence may lack a functional group that inhibits proteolytic activity. The peptide may be engineered to contain other functional groups known to one of skill in the art.
[0405] In vitro, the peptide hydrogels disclosed herein may allow cell invasion and proliferation in 3D constructs, allowing the hydrogels to serve as scaffolding matrices for tissue regeneration. The peptide hydrogels may show biocompatibility following subcutaneous implantation. Experiments show minimal cell debris or dead cells at the gel implantation site 7 days post-subcutaneous administration. Experiments further show minimal increases in cytokine concentration in the gel andDocket No. G2093-7013WO
[0406] surrounding tissues compared to naive tissues, suggesting the gel has insignificant acute inflammation effects.
[0407] Kits Comprising the Peptide Preparation
[0408] Kits comprising the peptide preparation are described herein. The kit may comprise the peptide preparation and a buffer solution. The buffer may be configured to induce self-assembly of the peptide prior to or concurrently with administration of the peptide. Each of the peptide preparation and the buffer may be included in a vial or chamber. For example, the kit may comprise a pre-filled packaging containing one or more of the preparation and the buffer. The kit may comprise one or more devices for use and / or delivery of the peptide preparation. The kit may comprise a mixing device. The kit may comprise a delivery device. In certain embodiments, the delivery device and / or mixing device may be the pre-filled packaging, for example, the kit may comprise a pre-filled syringe, spray bottle, ampule, or tube. FIG. 11 is a schematic diagram of the preparation packaged in an end-use container. The exemplary end-use container of FIG. 11 is a pre-filled syringe. The enduse container may be employed as a delivery device or a mixing device. The kit and / or any component of the kit may be sterile or sterilized. For example, the kit and / or any component may be sterilized using autoclave sterilization, optionally terminal autoclave sterilization.
[0409] Any one or more component of the kit may be autoclavable. The packaged kit may be autoclavable. Any one or more component of the kit may be sterilized or sterile. For example, any one or more component of the kit may be sterilized by autoclave. The sterilized one or more component may be packaged in a substantially air-tight container. In some embodiments, the packaged kit may be sterilized, e.g., by autoclave.
[0410] In certain embodiments, the kit may comprise the purified peptide in a dried or powder form. For example, the purified peptide may be lyophilized. The kit may comprise a biocompatible solution to be combined with the purified peptide to produce the peptide preparation. In other embodiments, the kit may comprise instructions to combine the purified peptide with a biocompatible solution to produce the preparation. The kit may additionally comprise the buffer solution.
[0411] The kit may comprise instructions for use. In particular, the kit may comprise instructions to combine the buffer with the preparation, optionally in the mixing device, to form the hydrogel. A user may be instructed to combine the preparation and the buffer at the point of use. In some embodiments, the user may be instructed to combine the preparation and the buffer prior to administration or concurrently with administration. The user may be instructed to apply the preparation and the buffer to the target site separately.Docket No. G2093-7013WO
[0412] The kit may additionally comprise instructions to store the kit under recommended storing conditions. For instance, the kit may comprise instructions to store the preparation or any component at room temperature (approximately 20-25 °C). The kit may comprise instructions to store the preparation or any component under refrigeration temperature (approximately 1-4 °C). The kit may comprise instructions to store the preparation or any component under freezer temperature (approximately 0 to -20 °C). The kit may comprise instructions to store the preparation or any component at body temperature (approximately 36-38 °C). The kit may comprise instructions to store the preparation or any component under cool and dry conditions.
[0413] The kit may additionally comprise an indication of expiration for the preparation or any component. The indication of expiration may be about 1 year after packaging. The indication of expiration may be between about 6 months and about 10 years after packaging, for example, between about 1 year and about 5 years after packaging.
[0414] The kit may comprise additional components for administration in combination with the preparation. In some embodiments, the kit may comprise instructions to combine the additional component prior to administration or concurrently with administration. The kit may comprise instmctions to administer the preparation and the additional component to the target site separately. The additional component may be or comprise an antibacterial formulation, an antiviral formulation, an antifungal formulation, an anti-tumor formulation, an anti-inflammatory formulation, a cell culture media, a cell culture serum, an anti-odor formulation, an analgesic, a hemostat formulation, local anesthetic, a pain-relief formulation, or a biological material. The additional component may be or comprise an anti-scarring agent and / or an axon regeneration agent. In some embodiments, the kit may further comprise a dressing, e.g., a topical dressing, a barrier dressing, and / or a wound dressing.
[0415] The kit may comprise one or more component configured to induce shear-thinning of the hydrogel. Mixing devices or delivery devices (described below) may be employed to induce shearthinning of the hydrogel by mechanical agitation. The kit may comprise one or more component selected from a temperature control device, a pH control additive, an ion chelator composition, a solvent, a sound control device, a lyophilization device, and an air drying device to induce shearthinning. For example, the kit may comprise a heater or cooler, a source of an acid or a base, a source of an ion chelator, a source of a solvent, a speaker or sound transmitter, a lyophilizer, or a compressed air dryer, or a fan.Docket No. G2093-7013WO
[0416] Mixing Devices
[0417] Mixing devices for preparation of a hydrogel at a point of care are disclosed herein. The device may be a multi-chamber device. In exemplary embodiments, the device may be a two-chamber device. The devices may include a first chamber for a peptide preparation. The preparation may comprise a self-assembling peptide in a biocompatible solution. The devices may include a second chamber for a buffer solution. The first chamber and the second chamber may be separated by a barrier provided to prevent fluid communication between the first chamber and the second chamber. The devices may, optionally, further comprise a mixing chamber. The mixing chamber may be fluidly connectable to the first chamber and the second chamber. Prior to mixing, the mixing chamber may be separated from the first chamber and / or the second chamber by a barrier. In other embodiments, the mixing device may be configured for direct mixing of the contents of the first and second chambers. In some embodiments, the devices may comprise a third chamber for an additional formulation or compound to be administered to the subject. The third chamber may be separated from the first chamber, the second chamber, and / or the mixing chamber. The third chamber may be fluidly connectable to the first chamber and / or the second chamber directly or via the mixing chamber.
[0418] The device may be a single use device. The device may be a multiple use device.
[0419] In an exemplary embodiment, each of the first, second, or third chamber may be a syringe barrel. Each barrel may have an associated plunger for agitation. Each barrel may be hermetically fitted to a coupling adapter, which forms the mixing chamber. The hermetic fitting may be, for example, a luer lock or luer taper connection.
[0420] The preparation and buffer may be agitated or otherwise mixed to form a homogenous or substantially homogenous mixture, inducing hydrogelation. In some embodiments, the preparation and buffer may be agitated by transferring the mixture back and forth between the first chamber and the second chamber. In some embodiments, the hydrogel exhibits shear-thinning properties, such that during agitation the mixture is substantially liquid. Upon settling, the mixture may form a solid or gel material.
[0421] The mixing device may be a static mixing device. A static mixer may generally comprise a device for substantially continuous mixing of the preparation without moving components. For example, the static mixer may comprise a cylindrical or rectangular housing with one or more inlet for each component to be mixed and a single outlet for the mixture. The static mixer may comprise a plate-type mixer.Docket No. G2093-7013WO
[0422] The mixing device may generally be formed or lined with an inert, thermally-stable material. In certain embodiments, the material may be opaque and / or shatter resistant.
[0423] Delivery Devices
[0424] In some embodiments, the kits may include a delivery device. For instance, the kits may include a syringe or catheter. The kits may include a dropper. The kits may include a spray, e.g. in conjunction with a bottle. The spray device may be, for example, a nasal spray. The kits may include a tube or ampule. The kits may include a film, for example. The type of delivery device may be selected based on a target indication. Additionally, the properties of the delivery device may be selected based on a target indication. For instance, a syringe for topical delivery of the preparation may have a larger passage than a syringe for injection of the preparation.
[0425] In some embodiments, the syringe may be used for topical application of the preparation. In other embodiments, the syringe may comprise a needle for parenteral application. The needle of the syringe may have a Birmingham system gauge between 7 and 34. The catheter may be used for parenteral application. The needle of the catheter may have a Birmingham system gauge between 14 and 26. The peptide may be formulated for administration through a particular gauge needle. For instance, the peptide may be selected to have a variable viscosity that will allow application of the preparation through a particular gauge needle.
[0426] In some embodiments, the spray bottle may be used for topical application of the preparation. The spray bottle may comprise a container for the preparation and a spray nozzle. The spray nozzle may be configured for targeted delivery to a target tissue. For instance, a spray nozzle for targeted delivery to an epithelial tissue may have a substantially flat surface and a spray nozzle for targeted delivery to an intranasal tissue may have a substantially conical surface. The spray nozzle may be configured to deliver a predetermined amount of the preparation. In some embodiments, the spray nozzle may be configured to deliver the preparation in substantially unidirectional flow, optionally, regardless of orientation of the spray bottle.
[0427] The spray nozzle may be configured to reduce retrograde flow. In certain embodiments, the spray nozzle may be spring-loaded. In other embodiments, the spray nozzle may be pressure actuated. The actuation pressure may be selected based on the variable viscosity of the preparation. For instance, the actuation pressure may be selected to be sufficient to dispense the hydrogel through the spray nozzle.Docket No. G2093-7013WO
[0428] The film may be used for topical application of the preparation. The film may be saturated with the preparation. The film may be used as a barrier dressing and / or hemostat. In some embodiments, the film may accompany a barrier dressing.
[0429] The delivery device may be a single use device. The delivery device may be a multiple use device. The delivery device may include a first chamber for a peptide preparation. The preparation may comprise a self-assembling peptide in a biocompatible solution. The delivery device may include a second chamber for a buffer solution. The first chamber and the second chamber may be separated by a barrier provided to prevent fluid communication between the first chamber and the second chamber. The delivery device may be constructed and arranged for administration of the peptide preparation and the buffer solution simultaneously or substantially simultaneously. In some embodiments, the delivery device may comprise a third chamber for an additional formulation or compound to be administered to the subject. The third chamber may be separated from the first chamber and / or the second chamber.
[0430] The delivery device may generally be formed or lined with an inert, thermally-stable material. In certain embodiments, the material may be opaque and / or shatter resistant.
[0431] Methods of Treatment by Administration of Peptide Hydrogels
[0432] In some embodiments, the preparations disclosed herein may be administered according to a predetermined regimen. The preparations disclosed herein may be administered daily, weekly, monthly, yearly, or bi-yearly.
[0433] The preparations disclosed herein may provide immediate release effects. For example, the onset of action of the active ingredient may be less than one minute, several minutes, or less than one hour.
[0434] The preparations disclosed herein may provide delayed release effects. For example, the onset of action of the active ingredient may be more than one hour, several hours, more than one day, more than several days, or more than one week.
[0435] The preparations disclosed herein may provide extended release effects. For example, the preparations may be effective for more than one day, more than several days, more than one week, more than one month, several months, or up to about 6 months.
[0436] The preparations disclosed herein may be administered in conjunction with a medical approach that treats the relevant disease or disorder or a symptom of the relevant disease or disorder. For example, the preparations may be administered in conjunction with a medical approach that is approved to treat the relative disease or disorder or a symptom of the relevant disease or disorder.Docket No. G2093-7013WO
[0437] The preparations may be administered in conjunction with a medical approach that is commonly used to treat the relevant disease or disorder or a symptom of the relevant disease or disorder.
[0438] The preparations disclosed herein may be administered in combination with a surgical treatment. The preparations disclosed herein may be administered to treat wounds associated with the surgical treatment and / or to prevent or treat biofilm.
[0439] The preparations disclosed herein may be administered in combination with an antiinflammatory agent or treatment. Anti-inflammatory agent may refer to a composition or treatment which reduces or inhibits local or systemic inflammation. The anti-inflammatory agent may comprise, e.g., non-steroidal anti-inflammatory drugs (NSAID), antileukotrienes, immune selective anti-inflammatory derivatives (ImSAID), and / or hypothermia treatment.
[0440] The preparations disclosed herein may be administered in combination with an antibacterial, antiviral, and / or antifungal agent. Such agents may refer to compositions or treatments which eliminate or inhibit proliferation of bacterial, viral, and / or fungal organisms, respectively. Exemplary antibacterial agents include antibiotics and topical antiseptics and disinfectants. The antiviral agent may be a target-specific antiviral agent or a broad-spectrum antiviral agent (e.g., remdesivir, ritonavir / lopinavir). Exemplary local antiviral agents include topical antiseptics and disinfectants. Exemplary antifungal agents include antifungal antibiotics, synthetic agents (e.g., flucytosine, azoles, allylamines, and echinocandins), and topical antiseptics and disinfectants.
[0441] The preparations disclosed herein may be administered to treat a wound, for example, an acute, a sub-acute, or a chronic wound. The wound may be a surgical wound, laceration, burn wound, bite / sting wound, vascular wound (venous, arterial or mixed), diabetic wound, neuropathic wound, pressure wound, ischemic wound, moisture-associated dermatitis, or result from a pathological process. In certain embodiments, the preparations may be administered in an amount effective to treat diabetic foot ulcers (DFU). In certain embodiments, the preparations may be administered in an amount effective to treat gastrointestinal wounds, such as anal fistulas, diverticulitis, and ulcers. In particular, the preparations may be administered in an amount effective to promote infection free wound closures.
[0442] The preparations disclosed herein may be administered in combination with a treatment or agent to provide anesthesia and / or pain-relief, e.g., local anesthetic. “Anesthetic” may refer to a composition which provides temporary loss of sensation or awareness. The anesthetic may be a general anesthetic (e.g., GABA receptor agonists, NMDA receptor antagonists, or two-pore potassium channel activators) or a local anesthetic (e.g., ester group agents, amide group agents, and naturally derived agents).Docket No. G2093-7013WO
[0443] The preparations may be administered in combination with an analgesic or pain-relief agent. “Analgesic” may refer to a composition for systemic treatment or inhibition of pain. The analgesic may comprise an anti-inflammatory agent or an opioid.
[0444] The preparations disclosed herein may be administered in combination with a hemostat agent. “Hemostat” may refer to a tool or composition to control bleeding. Exemplary hemostat compositions include collagen-based agents, cellulose-based agents, and chitosan-based agents.
[0445] The preparations disclosed herein may be administered in combination with a treatment or agent to enhance cell or tissue graft therapy. In certain embodiments, the preparations disclosed herein may be administered in combination with a treatment or agent to prevent or inhibit cell death and / or control or reduce inflammation. The preparations disclosed herein may be administered in combination with cell culture media or cell culture serum.
[0446] Any of the combination elements may be encapsulated in the hydrogel, for example, as an active agent, such as a tissue-active agent, or administered separately.
[0447] The administered peptide hydrogels may have an immediate local effect. For instance, the administered preparations may provide localized wound healing or injury treatment effects by closing the wound or filling a void. In certain embodiments, the administered hydrogels may have a systemic effect. For instance, the administered hydrogels may enable cell migration or communication between cell grafts and environmental cells, resulting in a systemic effect. In other embodiments, the administered hydrogels may enable delivery of cell products or byproducts, resulting in a systemic effect. The administered peptide hydrogels may have antimicrobial, antiviral, and / or antifungal properties at a localized site of administration. In other embodiments, the administered peptide hydrogels may provide systemic antimicrobial, antiviral, and / or antifungal properties.
[0448] The administered peptide hydrogels may have long-term, sustained antimicrobial, antiviral, and / or antifungal properties at a localized site of administration. The peptide may be designed to form a hydrogel having a direct contact antimicrobial, antiviral, antifungal effect. Thus, the hydrogel may eradicate microorganisms which directly contact the hydrogel at the target site. The hydrogel may be substantially free of encapsulated antimicrobial, antiviral, and / or antifungal agents.
[0449] Furthermore, the local antimicrobial, antiviral, and / or antifungal effect may persist as long as the hydrogel is in contact with the target tissue. FIG. 2 includes images which show sustained antimicrobial, antiviral, and / or antifungal effect at the target site.
[0450] To provide a systemic antimicrobial, antiviral, and / or antifungal effect, the peptide hydrogel may additionally comprise encapsulated antimicrobial, antiviral, and / or antifungal agents.Docket No. G2093-7013WO
[0451] Administration of such a hydrogel may generally provide: (1) local antimicrobial, antiviral, and / or antifungal treatment by direct contact as previously described, and (2) systemic antimicrobial, antiviral, and / or antifungal treatment as a vehicle of an encapsulated therapeutic agent.
[0452] The preparations disclosed herein may be formulated as a hemostat, debridement agent, or barrier dressing (e.g., antimicrobial, antifungal, or antiviral barrier dressing). The preparations may be formulated for wound treatment. Exemplary wounds which may be treated by administration of the preparation include partial and full thickness wounds (e.g., pressure sores, leg ulcers, diabetic ulcers), first and second degree burns, tunneled / undermined wounds, surgical wounds (e.g.. associated with donor sites / grafts, tissue and cell grafts, Post-Moh’s surgery, post laser surgery, podiatric, sound dehiscence), trauma wounds (e.g., abrasions, lacerations, burns, skin tears), gastrointestinal wounds (e.g., anal fistulas, diverticulitis, ulcers), and draining wounds. The preparations may be formulated for administration to a predetermined target tissue, for example, mesenchymal tissue, connective tissue, muscle tissue, nervous tissue, embryonic tissue, dermal tissue, bone tissue, dental tissue, corneal tissue, cutaneous tissue, integumental tissue, soft tissue, and hard tissue, or a biological fluid.
[0453] Methods of Treatment of Microbial Infection
[0454] The preparation may be formulated to provide antimicrobial properties upon administration at a target site. For example, the self-assembled polymeric hydrogel may have antimicrobial properties. As disclosed herein, “antimicrobial” properties may refer to an effect against a microbial population, e.g., killing or inhibiting one or more microorganism from a microbial population. Thus, methods of treating a microbial infection or killing or inhibiting proliferation of a target microorganism are disclosed herein. “Proliferation” may generally refer to the metabolic or reproductive activity of an organism. Methods of reducing or eliminating a microbial contamination are disclosed herein. Methods of management of a microbial bioburden are disclosed herein. The methods may generally comprise administering the preparation in an amount effective to promote deactivation of a target microorganism. In particular, a preparation comprising about 3.0% w / v or less of the peptide, for example, 1.5% w / v or less, or 1.0% w / v or less, may provide antimicrobial properties at a target site.
[0455] The methods may comprise identifying a subject as being in need of treatment for a microbial contamination, colonization, or infection. Tn general, a microbial colonization or infection may be induced by proliferation of a pathogenic microorganism (disease-causing microorganism). The microbial contamination may be identified by presence of one or more microorganism. In someDocket No. G2093-7013WO
[0456] embodiments, the methods may be employed for prevention or treatment of a microbial colonization or infection. The microbial colonization may refer to an established colony of one or more microorganism. The microbial infection may refer to an established colony of one or more microorganism which has been diagnosed by a clinical assessment. The microbial colonization or infection may be localized or systemic. In general, a microbial contamination may develop into a microbial colonization or infection if adequate treatment is not provided.
[0457] The preparation may be administered in an amount effective to treat biofilm or a microbial infection. The methods may generally comprise administering the preparation in an amount effective to promote deactivation of a pathogenic microorganism. In certain embodiments, the pathogenic microorganism may be a pathogenic bacterial organism. For example, the preparations and methods may be effective at promoting deactivation of broad-spectrum (gram-positive and gram-negative) bacteria. The pathogenic microorganism may be a species of a genus selected from Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, and Yersinia.
[0458] The preparation may be administered in combination with a surgical procedure. The methods may comprise administering the preparation in an amount effective to sterilize at least 90% of the target microorganism at the target site. For instance, the methods may comprise administering the preparation in an amount effective to sterilize at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, at least 99.9%, at least 99.99%, or at least 99.999% of the target microorganism at the target site. Exemplary target sites include epithelial tissue, gastrointestinal system tissue, respiratory system tissue, cardiac system tissue, nervous system tissue, reproductive system tissue, ocular tissue, auditory tissue, and bloodstream. Epithelial tissue may include, for example, epidermis, dermis, hair, and nail. However, additional target sites may be treated by the methods disclosed herein. As disclosed herein, sterilize may refer to any process that eliminates, removes, kills, or deactivates the microorganism at the target site.
[0459] Methods o f Treatment of Fungal Infection
[0460] The preparation may be formulated to provide antifungal properties upon administration at a target site. For example, the self-assembled polymeric hydrogel may have antifungal properties. As disclosed herein, “antifungal” properties may refer to an effect against a fungal population, e.g.,Docket No. G2093-7013WO
[0461] killing or inhibiting one or more organism from a fungal population. Thus, methods of treating a fungal infection or inhibiting proliferation of a fungal organism are disclosed herein. The methods may generally comprise administering the preparation in an amount effective to promote deactivation of a fungal organism. Methods of reducing or eliminating a fungal contamination are disclosed herein.
[0462] The methods may comprise identifying a subject as being in need of treatment for a fungal contamination, colonization, or infection. In certain embodiments, the preparation may be administered in an amount effective to treat at least one of biofilm, Tinea corporis. Candidiasis, Blastomycosis, Coccidioidomycosis, Histoplasmosis, Cryptococcosis, Paracoccidioidomycosis, Aspergillosis, Aspergilloma, Meningitis, Mucormycosis, Pneumocystis pneumonia (PCP), Talaromycosis, Sporotrichosis, and Eumycetoma of the subject.
[0463] The preparations and methods may be effective at promoting deactivation of broad-spectrum (sporulating and non-sporulating) fungal organisms. The preparation may be administered in an amount effective to treat a fungal infection associated with or inhibit proliferation of at least one of Aspergillus clavatus, Aspergillus fischerianus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus niger, Trichophyton mentagrophytes, Trichophyton rubrum, Microsporum canis, Candida albicans, Candida auris, Candida parapsilosis, Candida tropicalis, Blastomyces dermatitidis, Coccidioides immitis, Coccidioides posadasii, Cryptococcus gattii, Cryptococcus neoformans, Histoplasma capsulatum, Paracoccidioides brasiliensis, Pneumocystis jirovecii, Mucormycetes rhizopus, Mucormycetes mucor, Mucormycetes lichtheimia, Talaromyces mameffei, Sporothrix schenckii, Acremonium strictum, Noetestudina rosatii, Phaeoacremonium krajdenii, Pseudallescheria boydii, Curvularia lunata, Cladophilaophora bantiana, Exophiala jeanselmei, Leptosphaeria senegalensis, Leptosphaeria tompkinsii, Madurella grisea, Madurella mycetomatis, Pyrenochaeta romeroi, Trichosporon asahii, Cladosporium herbarum, and Fusarium sporotrichioides.
[0464] The methods may comprise administering the preparation in an amount effective to sterilize at least 90% of the fungal organism at the target site. For instance, the methods may comprise administering the preparation in an amount effective to sterilize at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, at least 99.9%, at least 99.99%, or at least 99.999% of the fungal organism at the target site. As disclosed herein, sterilize may refer to any process that eliminates, removes, kills, or deactivates the fungal organism at the target site.Docket No. G2093-7013WO
[0465] Methods of Treatment of Biofilm
[0466] The preparation may be formulated for treatment of biofilm. Thus, the methods disclosed herein may comprise treatment of biofilm. Treatment of biofilm may generally comprise eliminating at least a portion of biofilm or inhibiting biofilm formation. Administration of the preparation may have an effect against a biofilm population, for example, killing or inhibiting one or more organism in a biofilm community. In general, the charged peptide polymer hydrogel may deconstruct the polymicrobial fungal and bacterial biofilm barrier upon contact. While not wishing to be bound by theory, it is believed the preparations disclosed herein may be selected to dismantle extracellular matrix of the biofilm population, exposing fungal, viral, and microbial organisms of the biofilm to the cationic peptide of the hydrogel. The peptide hydrogel may be effective by destroying microbes, fungi, and viral organisms within biofilms. The preparation may be administered as an antifungal, antimicrobial, and / or antiviral peptide to destroy fungi, microorganisms, and / or viral organisms, e.g., in a biofilm population, through cell lysis.
[0467] Methods of management of biofilm are also disclosed herein. For example, the methods may be employed for prevention of biofilm. The preparation may be administered to a target tissue having a population of biofilm or identified as prone to developing biofilm, e.g., a wound or wounded tissue. The preparation may be administered in response to tissue contamination or odor.
[0468] The methods may generally comprise administering the preparation in an amount effective to promote treatment of biofilm and / or deactivation of a biofilm population. The biofilm population may comprise bacterial organisms, for example, gram-positive and / or gram-negative bacterial organisms. The biofilm population may comprise fungal organisms, for example, sporulating and / or non-sporulating fungal organisms. Thus, the preparation may provide treatment of biofilm by the antimicrobial and / or antifungal properties and methods described above. In certain embodiments, the biofilm population may comprise viral organisms. The preparation may provide treatment of biofilm by antiviral properties and methods described herein.
[0469] The preparation may be formulated as a biofilm removal agent. In some embodiments, the preparation may be administered to a target tissue for removal of biofilm. For example, the preparation may be administered for debridement of the biofilm and / or biofilm-infected tissue.
[0470] Methods of Treatment of Viral Infection
[0471] The preparation may be formulated to provide antiviral properties upon administration at a target site. For example, the self-assembled polymeric hydrogel may have antiviral properties. As disclosed herein, “antiviral” properties may refer to an effect against a viral population, e.g., killingDocket No. G2093-7013WO
[0472] or inhibiting one or more organism from a viral population. Thus, methods of treating a viral infection or inhibiting proliferation of a viral organism are disclosed herein.
[0473] The methods may comprise administering the preparation in an amount effective to sterilize at least 90% of the viral organism at the target site. For instance, the methods may comprise administering the preparation in an amount effective to sterilize at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, at least 99.9%, at least 99.99%, or at least 99.999% of the viral organism at the target site or systemically. In some embodiments, the methods may comprise administering the preparation in an amount effective to sterilize 100% of the viral organism at the target site or systemically. As disclosed herein, sterilize may refer to any process that eliminates, removes, kills, or deactivates the viral organism at the target site.
[0474] Methods of Administration of Peptide Hydrogels
[0475] The peptide hydrogels may be administered by any mode of administration known to one of skill in the art. The method of administration may comprise selecting a target site of a subject and administering the preparation to the target site. In certain embodiments, the methods may comprise mixing the peptide with a buffer configured to induce self-assembly of the peptide to form the hydrogel. In general, the peptide may be mixed with the buffer prior to administration. However, in some embodiments, the peptide may be combined with the buffer at the target site.
[0476] The target site may be any bodily tissue or bloodstream. In some embodiments, the target site may be epithelial tissue, gastrointestinal system tissue, respiratory system tissue, cardiac system tissue, nervous system tissue, reproductive system tissue, ocular tissue, or auditory tissue. The route of administration may be selected based on the target tissue. Exemplary routes of administration are discussed in more detail below.
[0477] In some embodiments, the methods may comprise identifying a subject in need of administration of the preparation. The methods may comprise imaging a target site or monitoring at least one parameter of the subject, systemically or at the target site. Exemplary parameters which may be monitored include temperature, pH, response to optical stimulation, and response to dielectric stimulation. The methods may comprise imaging the target site or monitoring at least one parameter of the subject prior to administration of the preparation, concurrently with administration of the preparation, or subsequent to administration of the preparation.
[0478] In certain embodiments, the preparation may be administered responsive to the measured parameter being outside tolerance of a target value. The preparation may be administered automatically or manually in response to the measured parameter.Docket No. G2093-7013WO
[0479] The preparation may be formulated for topical, parenteral, or enteral administration. The preparation may be formulated for systemic administration. Various pharmaceutically acceptable carriers and their formulations are described in standard formulation treatises, e.g., Remington’s Pharmaceutical Sciences by E.W. Martin. See also Wang, Y.J. and Hanson, M.A., Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2 S, 1988; Aulton, M. and Taylor, K., Aulton’ s Pharmaceutics: The Design and Manufacture of Medicines, 5th Edition, 2017; Antoine, A., Gupta M.R., and Stagner, W.C., Integrated Pharmaceutics: Applied Preformulation, Product Design, and Regulatoty Science, 2013; Dodou K. Exploring the Unconventional Routes -Rectal and Vaginal Dosage Formulations, The Pharmaceutical Journal, 29 Aug. 2012.
[0480] Parenteral Administration of Peptide Hydrogels
[0481] In certain embodiments, the hydrogels may be administered parenterally. In general, parenteral administration may include any route of administration that is not enteral. The preparation may be administered parenterally via a minimally invasive procedure. In particular embodiments, the parenteral administration may include delivery by syringe, e.g., by needle, or catheter. For instance, the parenteral administration may include delivery by injection. The parenteral administration may be intramuscular, subcutaneous, intravenous, or intradermal. The shear-thinning ability of the hydrogels may allow distribution through small lumens, while still providing minimally invasive treatment.
[0482] Topical Administration of Peptide Hydrogels
[0483] In certain embodiments, the hydrogels may be administered topically. In general, topical administration may include any external or transdermal administration. For instance, the target site for administration may be an epithelial tissue. In particular embodiments, the topical administration may be accompanied by a wound dressing or hemostat.
[0484] In certain embodiments, the preparation may be formulated as an aqueous solution. Aqueous solutions may provide uniform application over a larger topical surface.
[0485] The aqueous solution may be administered topically with a delivery device. For instance, the preparation may be formulated for administration by spray, aerosol, dropper, tube, ampule, or syringe. In exemplary embodiments, the preparation may be administered topically by syringe. In exemplary embodiments, the preparation may be administered topically by spray. Spray parameters which may be selected for administration include droplet size, spray pattern, capacity, spray impact, spray angle, and spray diameter. Thus, the methods may comprise selecting a spray parameter to correlate with the target site or target indication. For instance, a smaller spray diameter may beDocket No. G2093-7013WO
[0486] selected for administration to a small wound. A specific spray angle may be selected for administration to a target site which is difficult to reach. A denser spray pattern or larger droplet size may be selected for administration to a moist target site. In some embodiments, the spray may be, for example, a nasal spray.
[0487] Exemplary droplet sizes may be between 65 pm to 650 pm. For instance, fine droplets having an average diameter of 65 pm to 225 pm, medium droplets having an average diameter of 225 pm to 400 pm, or coarse droplets having an average diameter of 400 pm to 650 pm may be selected. The spray pattern may range from densely packed droplets to sparse droplets. The spray diameter may range from less than 1 cm to 100 cm. For instance, spray diameter may be selected to be between less than 1 cm and 10 cm, between 10 cm and 50 cm, or between 50 cm and 100 cm. Spray angle may range from 0° to 90°. For instance, spray angle may be selected to be between 0° and 10°, between 10° and 45°, or between 45° and 90°.
[0488] The peptide preparation may be in a substantially solid or gel-like form. For instance, the preparation may be formulated as a powder or gel. Powder preparations may comprise lyophilized peptides. In certain embodiments, powder preparations may comprise talcum powder or cornstarch. Gels may comprise or consist of the peptide in a self-assembled form, for example, the peptide in an aqueous biocompatible solution, optionally with a buffer. In other embodiments, the gels may further comprise a polymer, e.g., poloxamers, xanthan gum, gellan gum, locust bean gum, and carrageenan.
[0489] The preparation may be in a cream form. For instance, the preparation may be formulated as a cream, ointment, or lotion. The preparation may be formulated as a serum or oil. The preparation may be formulated as a salve. Ointments may comprise anhydrous dispersions of the peptide, e.g., in a mineral oil-white petroleum base. Serums may include oil-based products, gel-based formulas, or lightweight emulsions. Oil-based serums and oils typically include polyphenols, essential fatty acids, and antioxidants. Oil-based serums and oils may be free of preservatives, as they typically lack water. Gel-based serums and water-based serums may contain water, gums, thickeners, and / or optionally humectants.
[0490] Gel, lotion, ointment, cream, serum, oil and / or salve preparations may optionally comprise a thickener and / or emulsifier. Exemplary thickeners and emulsifiers include emulsifying wax, polysorbate 20, ceteareth 20, cellulose derivatives, guar gum, locust bean gum, xanthan gum, and gelatin. Such preparations may have a viscosity of at least about 1 mPa-s, 10 mPa-s, 100 mPa-s, 1 Pa-s, 5 Pa-s, 10 Pa-s, or 20 Pa-s at room temperature, e.g., between about 20 °C - 25 °C.
[0491] Ointments, lotions, salves, creams, serums, oils, and gels with greater viscosities may provide for a longer residence time than, for example, aqueous solutions. Such formulations may enhanceDocket No. G2093-7013WO
[0492] skin penetration and hydration. In certain embodiments, the longer residence time may further allow for a reduced dosing interval. Emulsions may comprise encapsulating agents, such as microspheres, microcapsules, nanoparticles, nanocapsules, micelles, liposomes, niosomes, dendrimers, or cyclodextrin complexes. The encapsulating agents may be used to provide timed or delayed release formulations.
[0493] The topical preparation may include cosmetically acceptable additives, such as one or more preservatives, fillers, bulking agents, fragrances, or colorants. In other embodiments, the preparation may be substantially free of additives. For example, the preparation may be substantially free of preservatives, fillers, bulking agents, fragrances, and / or colorants.
[0494] In some embodiments the preparation may consist or consist essentially of the peptide in an aqueous biocompatible solution. In some embodiments, the preparation may consist or consist essentially of the peptide in a buffer.
[0495] In some embodiments, the preparation may be formulated for topical administration with a film, membrane, or sheet. The film, membrane, or sheet may be a rigid, semi-flexible, or flexible substrate. In certain embodiments, the flexible or semi-flexible substrate may be configured to adopt a topological conformation of the target site. In general, the film, membrane, or sheet may be in the form of a substrate saturated with the preparation or hydrogel. The substrate may be rigid, semiflexible. or flexible. The film, membrane, or sheet may be administered as a barrier dressing and / or hemostat. The preparation may be administered topically with a film, membrane, or sheet and accompanied by a barrier dressing.
[0496] In certain embodiments, the preparation may be formulated for topical administration as an impregnated material. For instance, the preparation may be formulated for topical administration with a mask or bandage. The mask may be a thin flexible or semi-flexible substrate, such as a fabric, polymer, gel, cellulose, or collagen substrate, impregnated or loaded with the preparation or hydrogel. The mask may provide targeted delivery of the preparation or hydrogel. Exemplary masks include facial sheet masks, under eye masks or patches, spot patches or spot dots (optionally in other shapes, such as stars, triangles, etc.), forehead patches, chin patches, cheek patches, jawline or v-line lifting patches, nose patches or nose strips, neck masks, and / or chest masks. The mask may be self-adhesive or comprise an adhesive. The mask may be designed to be worn for a period of time, for example, 5-30 minutes, 10-20 minutes, or more, and then discarded. Excess preparation or hydrogel may be massaged or patted onto the skin after removal of the mask.
[0497] The bandage may be a flexible substrate, such as fabric (e.g., cotton), polymer, gauze, foam, or paper. The bandage may comprise an area impregnated or loaded with the hydrogel. The bandageDocket No. G2093-7013WO
[0498] may provide targeted delivery of the preparation or hydrogel. The bandage may comprise an area that is self-adhesive or comprises an adhesive. The bandage may be used as a barrier dressing.
[0499] The peptide formulated as a film, membrane, sheet, barrier dressing, or impregnated material may provide treatment by direct contact with target site. Conventional antimicrobial wound dressings rely on traditional antibiotics and function merely as a vehicle for antibiotic agents. However, the formulations described herein may be designed to provide a biophysical mode of cell-membrane disruption against broad-spectrum (gram-positive and gram-negative) bacterial cultures. Thus, the antimicrobial, antiviral, and / or antifungal peptide hydrogel film, membrane, sheet, barrier dressing, or impregnated materials may generally avoid concerns around minimum inhibitory bacterial concentrations typical to conventional small molecule loaded polymers. Instead, the peptide hydrogel disclosed herein may be designed to exert toxicity against gram-positive and gram-negative bacteria (including antibiotic resistant strains) while remaining cell-friendly, non-inflammatory, and non-toxic by selecting amino acid charge ratio of the peptide. Similarly, the peptide hydrogel disclosed herein may be designed to exert toxicity against fungal organisms (e.g., sporulating and non-sporulating fungal organisms) and / or viral organisms. The film, membrane, sheet, barrier dressing, or impregnated material disclosed herein may provide a temporary extracellular matrix scaffold for tissue regeneration.
[0500] The peptide hydrogels may be administered topically to any target site in need thereof.
[0501] Management of skin after a cosmetic procedure is described herein as one exemplary embodiment. However, it should be understood that many other topical target sites and treatments are envisioned, for example, as described herein.
[0502] Wound healing, e.g., diabetic wounds, is described herein as another exemplary embodiment. The wounds may include acute, sub-acute, and chronic wounds. The wound may be a surgical wound or ischemic wound. Chronic wounds such as venous and arterial ulcer wounds or pressure ulcer wounds, and acute wounds, such as those caused by trauma may be treated. In some embodiments, the preparation may be formulated as a film, barrier dressing, and / or hemostat. Administration of the preparation may accompany a barrier dressing and / or hemostat.
[0503] Treatment and / or management or inhibition of biofilm is described herein as another exemplary embodiment. Tissue hydration is described herein as another exemplary embodiment. Moisture management and / or exudate management of wounds or tissues is described herein as another exemplary embodiment. Tissue debridement is described herein as another exemplary embodiment. The preparation may be administered topically as a prophylactic, for example, inDocket No. G2093-7013WO
[0504] association with a wound. The preparation may be administered topically as an analgesic, for example, to a chronic wound or site of biofilm.
[0505] For any of the routes of administration disclosed herein, the methods may comprise administering a single dosage of the preparation. The site of administration may be monitored for a period of time to determine whether a booster or subsequent dosage of the preparation is to be administered. For example, the methods may comprise monitoring the site of administration. A parameter of the subject, optionally at the target site, may be monitored as previously described. The subject may be monitored hourly, every 2-3 hours, every 6-8 hours, every 10-12 hours, every 12-18 hours, or once daily. The subject may be monitored daily, every other day, once every few days, or weekly. The subject may be monitored monthly or bi-monthly. In certain embodiments, the subject may be monitored for a period of up to about 6 months. For example, the subject may be monitored for about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, or about 6 months.
[0506] The methods may comprise administering at least one booster or subsequent dosage of the preparation. For example, the methods may comprise administering a booster dosage to the target site at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days after the first dosage. The methods may comprise administering a booster dosage 1 week, 2 weeks, 3 weeks. 4 weeks, 5 weeks, or 6 weeks after the first dosage. The methods may comprise administering a booster dosage at least 2 weeks, at least 1 month, at least 6 months, or at least 1 year after the first dosage. In certain embodiments, at least a portion of the hydrogel may be present at the target site at the time of the booster dosage. In other embodiments, the hydrogel may be fully metabolized or otherwise eliminated from the target site at the time of the booster dosage.
[0507] Management of Skin After a Cosmetic Procedure
[0508] The peptide hydrogel preparations described herein have been found to provide a superior therapeutic effect in the treatment or prevention of symptoms and side effects associated with cosmetic procedures. The peptides disclosed herein may promote or facilitate deep tissue healing, enhance or support collagen regeneration, and improve patient outcomes.
[0509] Certain properties of the peptide hydrogel have a synergistic effect on treatment or prevention of these symptoms and side effects. For instance, the anti-microbial effect of the peptide hydrogel may provide protection against pathogenic invaders; the peptide hydrogel may form a three-Docket No. G2093-7013WO
[0510] dimensional cryoprotective cell matrix locally at the target site; the peptide hydrogel may reduce inflammation and redness at the target site; substantially alternating hydrophilic and hydrophobic residues may enhance skin and cell penetration; amino acids such as Arg, Lys, Vai, Tyr, Pro, and Glu may provide antimicrobial, immunomodulatory, tissue adhesion, and structural properties. Such properties of the hydrogel are believed to provide superior treatment or prevention of the symptoms and side effects associated with cosmetic procedures. As such, administration of the peptide hydrogels disclosed herein may reduce the length of time required for recovery after a cosmetic procedure and / or accelerate healing and / or regeneration of skin.
[0511] In accordance with certain embodiments, the peptides disclosed herein may provide accelerated healing by promoting re-epithelialization and wound closure, reducing recovery time. For instance, in certain embodiments, administration of the peptides disclosed herein may accelerate re-epithelization and / or wound closure by at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95% within 14 days from administration, as compared to a subject that did not receive administration of the peptides.
[0512] The peptides described herein may provide inflammation modulation, e.g., reduce inflammation, by reducing redness and reducing or soothing irritation post-procedure. For instance, in certain embodiments, administration of the peptides disclosed herein may reduce inflammation and / or irritation by at least 5%, 10%. 15%, 20%, or 25% within 48 hours from administration, as compared to skin within 1, 2, 3, 4, 5, or 6 hours from administration. In some embodiments, administration of the peptides disclosed herein may reduce redness by at least 40%, 45%, 50%, 55%, or 60% within 48 hours from administration, as compared to skin within 1, 2, 3, 4, 5, or 6 hours from administration.
[0513] The peptides described herein may provide antimicrobial protection, e.g., prevent posttreatment infection, by preventing bacterial colonization and / or biofilm formation. The peptides disclosed herein may provide or support collagen and / or elastin regeneration or production by stimulating tissue recovery and long-term skin rejuvenation. The peptides disclosed herein may provide skin hydration and barrier support, e.g., protect and hydrate skin, by protecting and restoring skin barrier integrity, reducing transepidermal water loss. The peptides described herein may reduce wrinkles and fine lines or reduce the appearance of wrinkles and fine lines and / or provide skin rejuvenation by stimulating collagen and / or elastin regeneration or production. In some embodiments, administration of the peptides disclosed herein may restore at least 15%, 20%, 25%, 30%, 35%, or 40% of normal skin barrier function, as measured by transepidermal water loss, withinDocket No. G2093-7013WO
[0514] 48 hours from administration, as compared to skin within 1, 2, 3, 4, 5, or 6 hours from administration.
[0515] Thus, in accordance with one aspect, there are provided methods of reducing length of a recovery phase or accelerating healing and / or regeneration of skin after a cosmetic procedure. In accordance with another aspect, there are provided methods of treating or preventing symptoms or side effects of a cosmetic procedure.
[0516] The preparations disclosed herein may be used to enhance recovery and reduce symptoms or side effects of cosmetic procedures that involve skin injury. Exemplary cosmetic procedures include laser resurfacing or dermabrasion procedures, microneedling or dermarolling, chemical peels, radiofrequency (RF) skin tightening, laser treatments, e.g., CO2 laser treatments and others, application of injectables, such as neurotoxins and fillers, cryotherapy, thread lifts, such as non-surgical face lifts, microblading, tattooing and permanent makeup, laser hair removal or intense pulsed light (IPL), tattoo removal procedures, and platelet rich plasma (PRP) injection. In some embodiments, the cosmetic procedure may be a surgical procedure. Exemplary surgical cosmetic procedures include skin tightening and / or fat reduction procedures, such as lifts, e.g., face lifts, arm lifts, lower body lifts, thigh lifts, etc., tummy tucks (abdominoplasty), panniculectomy, or liposuction, hair transplant procedures, such as implantation of follicles after follicular unit excision (FUE) or follicular unit transplantation (FUT), or other skin graft procedures, which may be in the form of micro grafting, slit grafting, or punch grafting, and others.
[0517] Additionally or alternatively, in certain embodiments, the preparations disclosed herein may provide treatment for hair loss. For example, administration of the preparation or hydrogel disclosed herein may reduce or inhibit hair loss, stimulate or improve hair regrowth, and / or improve or modulate follicular or tissue regeneration. While not wishing to be bound by theory, it is believed that administration of the preparation or hydrogel disclosed provides superior results in supporting hair transplant procedures, for example, by reducing the length of the recovery phase, accelerating healing and / or regeneration of skin, as well as improving follicular and / or tissue regeneration after the procedure.
[0518] Laser resurfacing is a dermatological procedure that uses focused light energy to treat the epidermal and dermal skin layers. Laser dermabrasion is a dermatological procedure that combines laser energy with mechanical resurfacing exfoliation. These laser treatments may improve skin texture, tone, and appearance by removing layers of damaged or aging skin. The procedures may stimulate collagen production and promote the growth of new, healthier skin. They are commonly used to treat wrinkles, scars, hyperpigmentation, and other skin irregularities.Docket No. G2093-7013WO
[0519] The laser treatment may be performed with an ablative laser, a non-ablative laser, or a fractional laser. Ablative laser energy typically removes the epidermis in a controlled manner, eliminating damaged cells, pigmentation irregularities, and superficial imperfections like fine lines and age spots. Ablative lasers may stimulate new epidermal cell growth, leading to smoother, more evenly toned skin. Ablative laser energy may exfoliate dead skin cells and promote faster skin turnover. In the dermis, ablative laser energy may trigger a wound-healing response and stimulate collagen remodeling, leading to improved skin elasticity, firmness, and reduction of deeper wrinkles and scars.
[0520] Non-ablative laser energy and fractional laser energy typically bypass the epidermis to deliver heat energy to deeper layers, such as the upper dermis and dermis. These lasers may tighten the epidermis by stimulating cell renewal without physically disrupting the skin barrier. In the dermis, non-ablative lasers and fractional lasers may induce controlled micro-injuries, which trigger the body's natural healing process to produce new collagen and elastin, helping to improve skin laxity, texture, and scars over time.
[0521] Thus, laser resurfacing and dermabrasion procedures may typically induce the production of collagen, elastin, and new skin cells by producing controlled micro-injuries on the skin, which trigger wound-healing processes. The micro-injuries may include thermal or physical wounds created by the laser in the epidermis and / or dermis layers. Following the laser resurfacing treatment, skin typically enters a recovery phase characterized by redness, swelling, and the potential for peeling or crust formation as it heals and regenerates.
[0522] The preparations disclosed herein may promote recoveiy of the skin, e.g., repairing microinjuries. Furthermore, with the creation of micro-injuries, there may be a risk of microbial infection. The preparations disclosed herein may treat or prevent microbial infections resulting from a cosmetic procedure. In certain embodiments, the preparations may be administered in an amount effective to prevent bacterial colonization and / or biofilm formation after a cosmetic procedure.
[0523] The preparations disclosed herein may promote healing after a hair transplant or other skin graft procedure. For instance, administration of the preparation or hydrogel disclosed herein may reduce follicle or skin graft rejection, reduce edema post-transplant, and / or provide immune modulation to improve acceptance or tolerance of the follicular or skin graft. In certain embodiments, the methods may comprise performing a cosmetic procedure on a subject. In other embodiments, the subject may have recently received a cosmetic procedure. The subject may be a human without preexisting co-morbidities, e.g., a subject that is not suffering from a disease or condition that mayDocket No. G2093-7013WO
[0524] otherwise impair the natural wound healing process. In other embodiments, the subject may be a human with a pre-existing co-morbidity.
[0525] The methods may comprise administering the preparation or hydrogel disclosed herein to a target tissue that received the cosmetic procedure. While not wishing to be bound by theory, it is believed the hydrogels disclosed herein may prevent or reduce symptoms or side effects of cosmetic procedures including, for example, infections, inflammation, and promote wound healing. For instance, the hydrogels disclosed herein may promote wound healing and / or provide modulation of an inflammatory response, reducing the length of the recovery phase and accelerating healing and / or regeneration of the skin.
[0526] The preparations disclosed herein may promote healing of partial thickness wounds or full thickness wounds. Partial thickness wounds may include wounds that destroy the epidermis and extend only partially into the dermis. Full thickness wounds may include wounds that extend through the epidermis and dermis. Full thickness wounds may also extend at least partially into the hypodermis or one or more subcutaneous tissues, e.g., fat, fascia, muscle, or bone.
[0527] In some embodiments, the methods may comprise topically administering the preparation or hydrogel to the target tissue. The target tissue may be an epithelial or integumental tissue, e.g., target skin. The target tissue may be a target epidermal tissue. Depending on the depth of the wound, the preparation or hydrogel may be administered topically to a dermal tissue and / or a hypodermal tissue. Thus, the target tissue may be an integumental tissue, such as an epidermal tissue, dermal tissue, and / or hypodermal tissue. In other embodiments, the methods may comprise parenterally administering the preparation or hydrogel to the target tissue. The target tissue for parenteral administration may be a dermal or hypodermal tissue. The target tissue for topical or parenteral administration may be on one or more of the face, forehead, eye region, cheek, nose, neck, scalp, head, shoulder, arm, hands, leg, underarm, torso, chest, feet, knee, ankle, calf, thigh, or buttocks of the subject.
[0528] In some embodiments, the preparation or hydrogel may be administered less than 1 hour, e.g., less than 30 minutes, less than 25 minutes, less than 20 minutes, less than 15 minutes, less than 10 minutes, or less than 5 minutes after the cosmetic procedure. In some embodiments, the preparation or hydrogel may be administered between 1 hour and 6 hours after the cosmetic procedure, for example, at least 6 hours, e.g., at least 12 hours, at least 24 hours, at least 48 hours, or at least 72 hours after the cosmetic procedure. In some embodiments, a second or booster dose of the preparation or hydrogel may be administered at least 6 hours, e.g., at least 12 hours, at least 24 hours, at least 48 hours, or at least 72 hours after an initial administration of the preparation or hydrogel.Docket No. G2093-7013WO
[0529] Additional doses of the preparation or hydrogel may be administered every 6 hours, every 12 hours, or every 24 hours. In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more additional doses of the preparation or hydrogel are administered after the initial administration.
[0530] The preparation or hydrogel may be administered in an amount effective to treat or prevent a symptom or side effect of the cosmetic procedure. Exemplary symptoms or side effects include redness, swelling, peeling, crust formation, itching, burning, scarring, erythema, contact dermatitis, milia, pain, discomfort, and combinations thereof. In some embodiments, the preparation or hydrogel may be administered in an amount effective to treat or prevent inflammation.
[0531] The preparation or hydrogel may be administered in an amount effective to treat or prevent a microbial infection at the target tissue, e.g., a microbial infection associated with the cosmetic procedure. The microbial infection may be a bacterial infection, a fungal infection, and / or a viral infection. In some embodiments, the preparation or hydrogel may be administered in an amount effective to treat or prevent the formation of biofilm at the target tissue.
[0532] The preparation or hydrogel may be administered in an amount effective to reduce length of a recovery phase or accelerate healing and / or regeneration of skin after the cosmetic procedure. The recovery phase of exemplary cosmetic procedures, such as laser resurfacing or dermabrasion procedures, may generally include an inflammatory phase characterized by an immune response that triggers redness, swelling, and warmth as blood flow increases, and a proliferative phase characterized by keratinocyte migration and production of collagen and elastin by fibroblasts. The recovery phase may last between 0-14 days.
[0533] In some embodiments, administration of the preparation or hydrogel may reduce the length of the recovery phase, as compared to a subject that was not administered the preparation or hydrogel after the cosmetic procedure. For instance, the recovery phase may be reduced to less than 14 days. In some embodiments, the recovery phase may be reduced to less than 7 days, e.g., less than 6 days, less than 5 days, less than 4 days, less than 3 days, less than 2 days, or less than 1 day.
[0534] The preparation or hydrogel may be administered to a subject in need of a cosmetic procedure and / or a subject who is planning to undergo a cosmetic procedure. The preparation or hydrogel may be administered to a subject that recently received a cosmetic procedure. The subject may have one or more skin indications commonly treated with cosmetic procedures, e.g., laser resurfacing or dermabrasion, such as fine lines and wrinkles, acne, acne scars, hyperpigmentation and / or melasma, age spots and / or sun spots, skin laxity, and / or uneven skin tone or texture.
[0535] The preparations disclosed herein may be administered in combination with an approach commonly used or approved for use after a cosmetic procedure, for example, after a laser resurfacingDocket No. G2093-7013WO
[0536] or dermabrasion procedure. Exemplary combination treatments include administration of an antiinflammatory agent, an ointment or moisturizer, a UV blocker, cold compress, analgesic or painrelief composition, antibacterial composition, antifungal composition, antiviral composition, cell culture media, cell culture serum, or hemostatic composition. Other combination treatments may be provided. The combination treatment may be administered prior to, after, or concurrently with administration of the preparation or hydrogel. The combination treatment may be combined with one or both of the preparation and the buffer.
[0537] The preparation or hydrogel may be administered in combination with a biological material. Exemplary biological materials are disclosed in U.S. Patent Application Publication No.
[0538] 2024 / 0366717 titled “ANTIMICROBIAL MATRIX FORMED FROM PEPTIDE HYDROGELS’’ (incorporated herein by reference in its entirety for all purposes) and include, for example, cells, e.g., multipotent stem cells, pluripotent stem cells, induced pluripotent cells, non-pluripotent cells, mesenchymal stem / stromal cells, bone marrow mononuclear cells, glial cells, progenitor cells, immune cells, specialized cells, terminally differentiated cells, islet cells or cells of the target tissue, cell-derived matter, e.g., secreted material, cell fragments, cell lysates, or other byproducts, secretomes, exosomes, proteins (e.g., signaling proteins), enzymes, semm, plasma, e.g., platelet rich plasma (PRP), spheroids, liposomes, growth factors, cytokines, chemokines, paracrine factors, autocrine factors, genetic material (e.g., RNA or DNA), vesicles, and / or granules, tissue material or tissue -derived material, biological fluids, e.g.. natural biological fluids or synthetic biological fluids, or combinations thereof.
[0539] In accordance with another aspect, there is provided a method of facilitating regeneration of skin after a cosmetic procedure. The method may comprise providing the preparations disclosed herein. The method may comprise providing instructions to administer an effective amount of the preparation to a target tissue that has received the cosmetic procedure. In some embodiments, the methods may include providing instructions to administer an effective amount of the preparation to the target tissue immediately after the cosmetic procedure, for example, less than 5 minutes, less than 10 minutes, less than 15 minutes, less than 20 minutes, less than 25 minutes, or less than 30 minutes after the cosmetic procedure. The methods may include providing instructions to administer at least one second or subsequent dose at least 6 hours, at least 12 hours, or at least 24 hours after the initial dose. The methods may include providing instructions to administer a second or subsequent dose every 6 hours, every 12 hours, or every 24 hours after a prior dose.
[0540] In some embodiments, the method may further comprise providing a buffer configured to induce self-assembly of the peptide into the hydrogel. The preparation and the buffer may beDocket No. G2093-7013WO
[0541] combined to form the hydrogel. In some embodiments, the method may comprise providing the preparation and the buffer combined in the form of the hydrogel. In some embodiments, the methods may comprise providing the preparation and the buffer separately. In such embodiments, the method may comprise providing instructions to combine the preparation and the buffer to form the hydrogel. The method may comprise providing instructions to administer an effective amount of the hydrogel to the target tissue.
[0542] The preparation may have a pH level of between about 4.0 and 8.0. In some embodiments, the preparation may have a substantially physiological pH level of between about 7.0 and 8.0. The preparation may have a pH level of between about 7.3 and 7.5. In other embodiments, the preparation may have a dermatologically compatible pH level of between about 5.5 and 7.0. The preparation may have a pH level of between about 5.5 and 6.5, for example, between about 6.3 and 6.5, or about 6.5.
[0543] The preparation may comprise an effective amount of a cationic or anionic salt. The cationic or anionic salt may be added in an amount effective to control pH of the preparation, for example, to be substantially physiological and / or dermatologically compatible. One exemplary salt is NaCl (e.g., 5.5 mM NaCl). In some embodiments, the preparation may comprise an effective amount of a dermatologically compatible buffer, such as an amino acid derived buffer. Exemplary amino acid derived buffers include histidine-based or glycylglycine solutions. In some embodiments, the preparation may comprise an effective amount of a zwitterionic buffer. Exemplary zwitterionic buffers include 2-[4-(2-hydroxyethyl)piperazin-l-yl]ethanesulfonic acid (HEPES) and 3-(N-morpholino)propanesulfonic acid (MOPS). In some embodiments, the preparation may comprise an effective amount of an organic acid and / or salt thereof, e.g., lactobionic acid, lactobionate salt, taurine, taurate salts, and combinations thereof. In some embodiments, the preparation may comprise an effective amount of a chelating buffer, e.g., phytic acid, sodium phytate, or a combination thereof.
[0544] Methods of Providing Cosmesis
[0545] The preparation or hydrogel disclosed herein may be administered to provide cosmesis. Certain properties of the self-assembling peptides have a synergistic effect on cosmesis procedures. For instance, the anti-microbial effect of the peptides may provide protection against pathogenic invaders; the peptides may form a three-dimensional cryoprotective cell matrix locally at the target site; the peptides may reduce inflammation and redness at the target site; substantially alternating hydrophilic and hydrophobic residues may enhance skin and cell penetration; amino acids such as Arg, Lys, Vai, Tyr, Pro, and Glu may provide antimicrobial,Docket No. G2093-7013WO
[0546] immunomodulatory, tissue adhesion, and structural properties. Such properties of the peptides are believed to provide superior treatment associated with cosmetic procedures. As such, administration of the preparation or hydrogel disclosed herein may accelerate healing and / or regeneration of skin.
[0547] The preparation or hydrogel described herein may provide inflammation modulation by reducing redness and irritation. For instance, in certain embodiments, administration of the preparation or hydrogel disclosed herein may reduce inflammation and / or irritation by at least 5%, 10%, 15%, 20%, or 25% within 48 hours from administration. In some embodiments, administration of the preparation or hydrogel disclosed herein may reduce redness by at least 40%, 45%, 50%, 55%, or 60% within 48 hours from administration.
[0548] Thus, in accordance with certain aspects, methods of providing cosmesis are disclosed herein. The methods may comprise administering a preparation comprising a peptide or hydrogel disclosed herein. The preparation or hydrogel may be administered in an amount effective to provide a therapeutic and / or cosmetic effect at the target tissue. The method may comprise administering to the subject an effective amount of the preparation or hydrogel to provide cosmesis.
[0549] Providing cosmesis may include, for example, improving skin integrity, improving skin surface topology, reducing or preventing degradation of collagen in the skin of a subject or increasing the collagen content in the skin of a subject, reducing or preventing inflammation in the skin or a hair follicle, preventing, limiting, or inhibiting progression of an appearance or effect of aging in the skin, preventing, limiting, or inhibiting skin inflammation, preventing, limiting, or inhibiting injury to skin integrity or condition, substantially maintaining a state of skin integrity or condition, preventing, limiting, or inhibiting a topographical change of a cutaneous layer of skin, etc.
[0550] The methods, and any aspects of the foregoing, may further comprise one or more of the steps: i) identifying a subject in need of a cosmesis procedure; and (ii) providing a preparation of the disclosure.
[0551] In any of the foregoing embodiments, and any aspects of the foregoing, when the term “preventing” is used the term may refers to at least a partial inhibition, for example a 10% inhibition, a 20% inhibition, a 30% inhibition, a 40% inhibition, 50% inhibition, a 60%Docket No. G2093-7013WO
[0552] inhibition, a 70% inhibition, an 80% inhibition, a 90% inhibition, a 95% inhibition or greater than 95% inhibition.
[0553] In certain embodiments, the methods may comprise treating or preventing skin wrinkles. In certain aspects of this embodiment, the administration decreases wrinkle length, decreases wrinkle depth, decreases the number of wrinkles in a defined area, decreases the spacing between wrinkles, or a combination of the foregoing.
[0554] In some aspects, at least one wrinkle treated in the subject may comprise a fine line, surface line, or deep furrow. An amount and / or a frequency of administration may be sufficient to decrease an appearance, e.g., severity, of wrinkle in the subject. An amount and / or a frequency of administration may be sufficient to decrease a width of wrinkle in the subject. An amount and / or a frequency of administration may be sufficient to decrease a length of wrinkle in the subject. An amount and / or a frequency of administration may be sufficient to decrease a depth of wrinkle in the subject.
[0555] An amount and / or a frequency of administration may be sufficient to treat, inhibit, or prevent the progression of at least one of scarring (e.g., scar relating to sunburn, bed sore, wound, inflammatory lesion, or burn), skin thickening (e.g. keloid scarring), crack, fissure, heloma, sebum secretion, skin thickening, wrinkle, sun spot, skin tag, dark patch, stretch mark, spider vein, varicose vein, age spot, or pore appearance in the subject. An amount and / or a frequency of administration may be sufficient to reduce, inhibit, or prevent the progression of blotchiness or discoloration (e.g., vitiligo or post-inflammatory hyperpigmentation) associated with skin of the subject. An amount and / or a frequency of administration may be sufficient to reduce, inhibit, or prevent the progression of freckles associated with skin of the subject. An amount and / or a frequency of administration may be sufficient to promote firmness, hydration, elasticity, radiance, tone evenness, visual smoothness, or tactile smoothness associated with skin of the subject.
[0556] An amount and / or frequency of administration may be sufficient to modify or reduce a score of a parameter on the Griffiths’ 10-point scale, for example, as graded by the subject or a clinical grader, according to the following medical definitions (with half-point scores assigned as necessary to accurately describe the skin condition):
[0557] 0 = none (best possible condition)
[0558] 1 to 3 = mildDocket No. G2093-7013WO
[0559] 4 to 6 = moderate
[0560] 7 to 9 = severe (worst possible condition).
[0561] Exemplary parameters include oily appearance (shine and feel) with 0 = no shine, flat / matte appearance and 9 = strong shiny / oily appearance; pore appearance with 0 = small, tight, barely perceptible pores and 9 = large, noticeable pores; radiance with 0 = radiant, luminous appearance and 9 = dull / matte and or sallow appearance; blotchiness with 0 = no blotchines s / clear and 9 = blotchy skin appearance; skin tone (color) evenness with 0 = even, healthy skin color and 9 = uneven, discolored appearance; visual smoothness with 0 = smooth, even looking skin texture and 9 = rough, uneven looking skin texture; and tactile smoothness with 0 = smooth, even feeling skin texture and 9 = rough, uneven feeling skin texture. The modification or reduction of score may be by 9 points, 8 points, 7 points, 6 points, 5 points, 4 points, 3 points, 2 points, or 1 point.
[0562] In some aspects, administering an effective amount of the preparation or hydrogel may limit or inhibit injury to skin integrity of a cutaneous layer of skin in the subject. Administering an effective amount of the preparation or hydrogel may prevent an undesired topographical change of the cutaneous layer of skin in the subject. Administering an effective amount of the preparation or hydrogel may slow progression from a first topographical, structural, or matrix profile to a second topographical, structural, or matrix profile associated with the cutaneous layer of skin in the subject. In some aspects, the cutaneous layer may pertain to an epidermis (e.g. stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum, or stratum basalis), a basement membrane, a dermal-epidermal junction, a dermis (e.g. papillary dermis, reticular dermis, or any vasculature comprising the dermis), or subcutis (e.g. subcutaneous fat layer) of the subject.
[0563] In some aspects, administering an effective amount of the preparation or hydrogel may treat or prevent a change in skin pigmentation. Treating or preventing a change in skin pigmentation may include treating, preventing, limiting, or inhibiting a change in melanocyte function. The change in melanocyte function may be associated with one or more of vitiligo, senile lentigines, mottled pigmentation, reticular pigmentation, punctate pigmentation, ectopic pigmentation, perifollicular pigmentation, interfollicular pigmentation, hypopigmentation or hyperpigmentation (e.g., patchy, focal, or diffuse hypopigmentation or hyperpigmentation), erythema, scaling, and telangiectasia. The change in skin pigmentation and / or melanocyteDocket No. G2093-7013WO
[0564] function may be local or systemic.
[0565] Treating or preventing a change in skin pigmentation may include treating, preventing, limiting, or inhibiting a change in dermal pigmentation and / or epidermal pigmentation (e.g., basal and / or suprabasal pigmentation). In certain embodiments, the change may comprise formation of localized high and low pigmentation in a dermal layer. In some embodiments, the change may comprise increased pigmentation in an epidermal layer. The change in skin pigmentation may be associated with hyperplasia, acanthosis, hyperkeratosis, parakeratosis, orthokeratosis, hypomelanosis, melanogenesis, and / or increase epidermal thickness.
[0566] In some aspects, the skin of the subject may be substantially non-diseased. The skin of the subject may be substantially uninjured. The skin of the subject may be substantially free of inflammatory lesions. The skin of the subject may be substantially free of a mild to severe crack, fissure, or wrinkle. The skin of the subject may be substantially free of a mild to severe scar (e.g., scar relating to sunbum, bed sore, wound, inflammatory lesion, or burn) or stretch mark. The skin of the subject may be substantially free of a mild to severe sun spot, dark patch, or age spot. The skin of the subject may be substantially free of a mild to severe heloma, skin thickening, skin tag, or keloid scar. The skin of the subject may be substantially free of an appearance of a varicose vein or a spider vein. The skin of the subject may be substantially free of a mild to severe appearance of pores. The skin of the subject may be substantially free of mild to severe cellulitis.
[0567] The preparation or hydrogel may be administered to a target tissue. In certain embodiments, the target tissue may be an integumental tissue, for example, a tissue selected from an epidermal, dermal, or hypodermal tissue.
[0568] In some embodiments, the methods may comprise topically administering the preparation or hydrogel to the target tissue. The target tissue may be an epidermal tissue. In other embodiments, the methods may comprise parenterally administering the preparation to the target tissue. The target tissue may be a dermal or hypodermal tissue. The target tissue may be on one or more of the face, forehead, eye region, cheek, nose, neck, scalp, head, shoulder, arm, hands, leg, underarm, torso, chest, feet, knee, ankle, calf, thigh, or buttocks of the subject.
[0569] The preparations described herein may provide antimicrobial protection by preventing bacterial colonization and biofilm formation. The preparations disclosed herein may provide collagen and / or elastin regeneration or production by stimulating tissue recovery and long-termDocket No. G2093-7013WO
[0570] skin rejuvenation. The preparations disclosed herein may provide skin hydration and barrier support by protecting and restoring skin barrier integrity, reducing transepidermal water loss. The preparations described herein may reduce wrinkles and fine lines or reduce the appearance of wrinkles and fine lines and / or provide skin rejuvenation by stimulating collagen and / or elastin regeneration or production. In some embodiments, administration of the preparation or hydrogel disclosed herein may restore at least 15%, 20%. 25%, 30%, 35%, or 40% of normal skin barrier function, as measured by transepidermal water loss, within 48 hours from administration.
[0571] The administered preparations may have anti-inflammatory properties at a localized site of administration. In certain embodiments, the administered preparations may provide systemic anti-inflammatory properties.
[0572] The administered preparations may have antimicrobial, antiviral, and / or antifungal properties at a localized site of administration. In certain embodiments, the administered preparations may provide systemic antimicrobial, antiviral, and / or antifungal properties.
[0573] EXAMPLES
[0574] The function and advantages of these and other embodiments can be better understood from the following examples. These examples are intended to be illustrative in nature and are not considered to be limiting the scope of the invention.
[0575] Example 1: Application of Hydrogel After Laser Procedure
[0576] A preliminary study was performed to examine the efficacy and tolerability of the hydrogel after a laser procedure performed by a healthcare provider. In the study, the healthcare provider topically applied a hydrogel having 1.5% w / v of the peptide to the affected area immediately after performing a laser procedure. Subjects were then instructed to apply a second dose of the hydrogel before bed (approximately 4-12 hours after the initial application). Subjects were given the option to apply a third and fourth dose of the hydrogel the following day in the morning and evening, respectively (approximately every 12 hours after application of the second dose).
[0577] The clinical observations from a small number of patients that participated in the study indicated that topical application of the hydrogel was well tolerated after the laser procedure.
[0578] Furthermore, redness, swelling, and irritation post-procedure were significantly reduced, allowing patients to return to activities of daily living much faster. Typically, the recovery time for a laserDocket No. G2093-7013WO
[0579] procedure is about 5 days. The patients that received application of the hydrogel reported a recovery time of less than 5 days after the laser procedure.
[0580] Accordingly, topical administration of the hydrogel after a cosmetic procedure, such as a laser procedure, was well tolerated and showed a reduced recovery phase and accelerating healing of skin after the procedure.
[0581] Example 2: Prophetic Examples of Management of Skin After Cosmetic Procedures Management of Skin After Microneedling
[0582] The peptides disclosed herein will be administered for management of skin after a microneedling cosmetic procedure.
[0583] A healthcare provider will perform a microneedling procedure on a section of facial skin of a subject, in accordance with established protocols. After the microneedling procedure, the healthcare provider will topically apply a serum formulation containing the peptide disclosed herein in a concentration between 0.25% w / v and 6.0% w / v to the affected area of the skin from a dropper. Tolerability and efficacy of the formulation in reducing length of the recovery phase, accelerating healing and / or regeneration of the skin, and treating or preventing a symptom or side effect of the procedure will be evaluated for at least 14 days after the procedure.
[0584] ft is expected that administration of the serum formulation will reduce redness of the treated skin by 50% within 48 hours after the procedure, as compared to redness of the treated skin within 6 hours of after the procedure. It is also expected that administration of the serum formulation will accelerate wound closure of the micro-injuries by 75% within 14 days, as compared to a subject who did not receive administration of the serum formulation after a similar microneedling procedure.
[0585] Management of Skin After Dermabrasion
[0586] The peptides disclosed herein will be administered for management of skin after a dermabrasion cosmetic procedure.
[0587] A healthcare provider will perform a dermabrasion procedure on a section of facial skin of a subject, in accordance with established protocols. After the dermabrasion procedure, the healthcare provider will topically apply a hydrogel of the peptide disclosed herein in a concentration between 0.25% w / v and 6.0% w / v to the affected area of the skin from a tube. Tolerability and efficacy of the hydrogel in reducing length of the recovery phase, accelerating healing and / or regeneration of the skin, and treating or preventing a symptom or side effect of the procedure will be evaluated for at least 14 days after the procedure.Docket No. G2093-7013WO
[0588] It is expected that administration of the hydrogel will prevent bacterial colonization at the treated area of skin after the procedure. It is also expected that administration of the hydrogel will restore 25% of skin barrier function within 48 hours after the procedure, as compared to skin barrier function of the treated skin within 6 hours of after the procedure. Skin barrier function will be quantified by measuring transepidermal water loss.
[0589] Management of Skin After Laser Resurfacing
[0590] The peptides disclosed herein will be administered for management of skin after a laser resurfacing cosmetic procedure.
[0591] A healthcare provider will perform a laser resurfacing procedure on a section of facial skin of a subject, in accordance with established protocols. After the laser resurfacing procedure, the healthcare provider will topically apply a sprayable solution formulation containing the peptide disclosed herein in a concentration between 0.25% w / v and 6.0% w / v to the affected area of the skin. Tolerability and efficacy of the formulation in reducing length of the recovery phase, accelerating healing and / or regeneration of the skin, and treating or preventing a symptom or side effect of the procedure will be evaluated for at least 14 days after the procedure.
[0592] It is expected that administration of the sprayable formulation will alleviate pain and reduce inflammation at the affected area. It is also expected that subjects receiving administration of the sprayable formulation will be able to resume daily activities sooner than subjects who did not receive administration of the sprayable formulation after a similar laser resurfacing procedure.
[0593] Example 3: Temperature Stability of the Formulation
[0594] Temperature stability of the preparation was tested by examining antimicrobial efficacy and self-assembly after heat treatment. The formulation retained antimicrobial efficacy and self-assembly after heat sterilization.
[0595] Briefly, the formulation was prepared with a six-arginine peptide at 0.75% w / v. Gelation was induced by combination with a buffer having BTP as a biological buffering agent at a concentration of 33mM. The preparation was subjected to moist heat sterilization at 125 °C. Antimicrobial activity of the preparation was compared to non-heat sterilized gels, and 0.2 pm filtered gels. The antimicrobial activity was determined by placing lOuL of bacteria (106CFU) onto a sterile agar plate and then covering the inoculum with the experimental formulation. The treated inoculum was then incubated at 37 °C for 24 hours.Docket No. G2093-7013WO
[0596] Self-assembly results are presented in the graphs of FIGS. 15A-15B. FIG. 15A shows rheology of the non-heat sterilized gels. FIG. 15B shows rheology of the heat sterilized gels. Both samples displayed properties of self-assembly. Additionally, there was no significant difference in the maximum strain between the two samples.
[0597] Antimicrobial activity results are presented in the graph of FIG. 16. The heat sterilized samples showed a greater than 6-log reduction of bacteria. As shown in FIG. 16, the heat sterilized hydrogels show markedly increased antimicrobial activity as compared to non-heat sterilized hydrogels.
[0598] Another experimental sample of the peptide hydrogel was sterilized by passing through a 0.2 pm aseptic filter. Aseptic filtration also achieved greater than 6-log reduction of bacteria. However, the sterilization method poses potential for loss of peptide.
[0599] Peptide stability after heat sterilization was also tested. The results are shown in the graphs of FIGS. 17A-17B. Briefly, Ultra-Performance Liquid Chromatography (UPLC) of heat sterilized and non-heat sterilized hydrogels showed peaks at the same retention time (5.2 minutes and 5.3 minutes, respectively), confirming that the six-arginine peptide was present in both hydrogels. FIG. 17A shows UPLC data of the non-heat sterilized hydrogel. FIG. 17B shows UPLC data of the heat sterilized hydrogel. Additionally, the chromatographs showed no additional peaks in the heat sterilized hydrogels compared to the non-heat sterilized hydrogels. The results demonstrate that the peptide did not degrade during the heat-sterilization process.
[0600] Accordingly, the heat sterilized preparation exhibits antimicrobial activity (> 6-log reduction), self-assembles into a hydrogel (G’>100 Pa), and is stable / non-degraded after heat sterilization.
[0601] Example 4: Shelf-Stability of Formulation
[0602] Antimicrobial efficacy and rheology of the preparation were tested after a period of storage, to show shelf-stability. The formulation retained antimicrobial efficacy, exhibited gelation, and allowed for cell viability and proliferation after storage.
[0603] Briefly, the formulation was prepared with a six-arginine peptide at 0.75% w / v. Gelation was induced by combination with a buffer. The buffer included one of BTP, acetate, citrate, phosphate, and Tris as a biological buffering agent at varying concentrations of 33 mM, 50 mM, and 100 mM. The gels were stored for 1 day or 7 days. Morphology was determined by visual inspection.
[0604] Rheology was tested to determine the strain at which the gel becomes a liquid. AntimicrobialDocket No. G2093-7013WO
[0605] efficacy was tested against gram-positive MRSA (ATCC 33591) and gram-negative P. aeruginosa (ATCC 9027). The results are presented in Table 6 and the graphs of FIGS. 13 and 14A-14B.
[0606] Table 6: Formulation at 7 Days Post-Manufacture
[0607] Buffer (0.75% „ , Antimicrobial activity Antimicrobial activity against M’ / v PEP6R, pHFinalRheology against P. aeruginosa MRSA (growth of bacteria morphology (strain %) (growth of bacteria (%)) (%))
[0608] 1 day 7 day 1 day 7 day BTP 33mM ; Clear gel 1 _2_5.8............ ; ........0.000....... i ............0.000 ...........0....0.0...0. i ; r 0i.070503 50mM i Clear gel
[0609] lOOmM i Clear gel . 12514.1.01000.1.11650. 1.0)003.1 .51600. Acetate 33mM i Clear liquid . - . 1. 01026.1.0.000. ] . 0.000.1. 311503.
[0610] 50mM i Clear liquid i 0.000 1 0.002 § 0.005 i 8.660 lOOmM i Clear liquid i 0.000 i 0.000 0.001 i 1.376 Citrate 33mM i Cloudy . - . i . 01000. i .11147. 01000. 01003.
[0611] i liquid
[0612] 50mM | Cloudy . - . f . 01000.1. 1.087. 01003. 'i . 01004.
[0613] i liquid
[0614] lOOmM Cloudy | 7.580 i 88.200 0.013 'i 0.013 i liquid
[0615] Phosphate i .
[0616] 33mM iCloudy 0.000 i 0.000 7.580 | 13.467 i liquid
[0617] 50mM i Cloudy i 0.000 i 0.000 7.580 I 13.467 i liquid
[0618] lOOmM i Cloudy i 2.532 ; 1.001 5.053 i 6.286 i _ liquid _ ; ........ ....... | ........... | ......2(.... Tris 33mM i Clear gel
[0619] 50mM i Clear gel 99.69 . i ........0 __._000........ i , .3.970. | ...........0.001........... i ; .0.008...........
[0620]
[0621] lOOmM j Clear gel
[0622] The reported values of <0.001% growth correspond to a greater than 4-log reduction of bacteria, the FDA standard for antimicrobial activity. The formulation having 33 mM BTP showed an antimicrobial efficacy of greater than 6-log reduction against the test pathogens and formed a gel as measured by rheological properties having G’>100 Pa. FIG. 13 shows rheology data of the formulation having 33 mM BTP in storage modulus (G”) and loss modulus (G’). The cross over point represents the strain percentage at which the gel (G’) converts to a solution state (G”). FIGS. 14A-14B includes graphs showing antimicrobial activity of different buffer formulations tested against the P. aeruginosa (FIG. 14A) and MRSA (FIG. 14B) at 1 and 7 days after gel manufacture. The black dotted line represents 4 log reduction of bacteria (0.01 % growth) compared to the control inoculum of 106-l 07CFU. The red dotted line represents 6 log reduction of bacteria (0.0001% growth) compared to the control inoculum of 106-l 07CFU.
[0623] Cytocompatibility assays were also performed. All hydrogels made with BTP and Tris displayed strong cell viability and proliferation of murine mesenchymal stem cells.Docket No. G2093-7013WO
[0624] Accordingly, the hydrogel retains antimicrobial efficacy, rheological properties, and cytocompatibility after 7 days of storage. It is expected that the hydrogel will maintain similar properties after a longer period of storage.
[0625] Example 5: Long-Term Shelf-Life Stability of the Formulation
[0626] Shelf-life stability of the preparation was tested under different time and temperature conditions. Shelf-life stability was determined by measuring antimicrobial efficacy and selfassembly.
[0627] The formulation was prepared as described in Example 3 and stored at room temperature for 1, 10, 40, and 180 days, as described generally in Example 4. Antimicrobial activity was tested against 106CFU MRSA. The results are shown in FIG. 18.
[0628] Briefly, as shown in FIG. 18, the black dotted line indicates 4-log reduction as compared to the control. All tested samples displayed antimicrobial efficacy greater than 6-log reduction of bacteria, as indicated by the red dotted line. Thus, the tested formulation retained antimicrobial efficacy at all tested time points, up to 180 days.
[0629] The preparation was also tested for cytocompatibility. The results are presented in the graph of FIG. 19. All tested samples showed cell viability greater than 100%.
[0630] Accordingly, the heat sterilized preparation is shelf-stable up to 180 days post-manufacture, as shown by antimicrobial activity and cell viability. Viability trials for longer term stability are ongoing. However, similar results are expected for preparations stored more than 180 days.
[0631] Example 6: Rheological Evaluation of Hydrogel Extruded Through Syringe
[0632] Modulus of the hydrogel during extrusion through a syringe was evaluated. The formulation was prepared with a six-arginine peptide as described in Example 3. Gelation was induced by combination with a buffer. The preparation was steam sterilized as also described in Example 3.
[0633] The hydrogel was loaded into a Cyclo-Olefin-Polymer (COP) syringe as shown in FIG. 11 and extruded through the syringe opening. Rheology of the hydrogel during and after extrusion and self-assembly was measured. The rheology data are shown in the graph of FIG. 20.
[0634] During extrusion, the hydrogel viscosity is expected to decrease under the applied mechanical stress from the syringe. After extrusion, the preparation is expected self-assemble into the hydrogel. As shown in FIG. 20, the hydrogel reversibly self-assembles after applied mechanical stress from the syringe.Docket No. G2093-7013WO
[0635] Example 7: Treatment of Full-Thickness Wound Infected with MRSA
[0636] Effectivity of the hydrogel at 0.75% w / v and 1.5% w / v of the peptide were tested in the treatment of full-thickness wounds infected with MRSA.
[0637] Briefly, full-thickness incisions were created in mice as previously described. The incisions were infected with MRSA microbial colony. The infected wounds were treated with control, 0.75% w / v peptide hydrogel, or 1.5% w / v peptide hydrogel. MRSA proliferation was measured at 24 hours post-infection. The results are presented in the graph of FIG.19.
[0638] As shown in the graph of FIG. 12, treatment with both 0.75% w / v and 1.5% w / v peptide preparations reduced microbial proliferation, as compared to the control. Furthermore, there was no significant difference between treatment with 0.75% w / v peptide preparation and treatment with 1.5% w / v peptide preparation.
[0639] The phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. As used herein, the term “plurality” refers to two or more items or components. The terms “comprising,” “including,” “carrying,” “having,” “containing,” and “involving,” whether in the written description or the claims and the like, are open-ended terms, i.e., to mean “including but not limited to.” Thus, the use of such terms is meant to encompass the items listed thereafter, and equivalents thereof, as well as additional items. Only the transitional phrases “consisting of’ and “consisting essentially of,” are closed or semi-closed transitional phrases, respectively, with respect to the claims. Use of ordinal terms such as “first,” “second,” “third,” and the like in the claims to modify a claim element does not by itself connote any priority, precedence, or order of one claim element over another or the temporal order in which acts of a method are performed, but are used merely as labels to distinguish one claim element having a certain name from another element having a same name (but for use of the ordinal term) to distinguish the claim elements.
[0640] Having thus described several aspects of at least one embodiment, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Any feature described in any embodiment may be included in or substituted for any feature of any other embodiment. Such alterations, modifications, and improvements are intended to be part of this disclosure and are intended to be within the scope of the invention. Accordingly, the foregoing description and drawings are by way of example only.
[0641] Those skilled in the art should appreciate that the parameters and configurations described herein are exemplary and that actual parameters and / or configurations will depend on the specificDocket No. G2093-7013WO
[0642] application in which the disclosed methods and materials are used. Those skilled in the art should also recognize or be able to ascertain, using no more than routine experimentation, equivalents to the specific embodiments disclosed.
Claims
Docket No. G2093-7013WOCLAIMS1. A method of reducing length of a recovery phase or accelerating healing and / or regeneration of skin after a cosmetic procedure, comprising:administering the cosmetic procedure to target skin of a subject; andadministering to the target skin a preparation comprising a purified amphiphilic peptide in an aqueous biocompatible solution, the peptide comprising a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern, the peptide being configured to self-assemble into a hydrogel.
2. A method of treating or preventing a symptom or side effect of a cosmetic procedure, comprising:administering the cosmetic procedure to target skin of a subject; andadministering to the target skin a preparation comprising a purified amphiphilic peptide in an aqueous biocompatible solution, the peptide comprising a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern, the peptide being configured to self-assemble into a hydrogel.
3. The method of claim 1 or claim 2, wherein the cosmetic procedure comprises a laser resurfacing or dermabrasion procedure, microneedling or dermarolling, chemical peel, radiofrequency (RF) skin tightening, laser treatment, application of an injectable, cryotherapy, thread lift, microblading, tattooing or permanent makeup, laser hair removal or intense pulsed light (IPL), a tattoo removal procedure, platelet rich plasma (PRP) injection, or a surgical cosmetic procedure.
4. The method of claim 3, wherein the surgical cosmetic procedure comprises a skin tightening procedure, a fat reduction procedure, or a hair transplant procedure.
5. The method of claim 1, wherein accelerating healing and / or regeneration of skin comprises at least one of:accelerating re-epithelization by at least 75% within 14 days of administration; reducing inflammation and / or irritation by at least 10% within 48 hours from administration; reducing redness by at least 50% within 48 hours from administration; andrestoring at least 25% of normal skin barrier function as measured by transepidermal water loss within 48 hours from administration.Docket No. G2093-7013WO6. The method of claim 2, wherein the symptom or side effect is redness, swelling, peeling, crust formation, itching, burning, scarring, erythema, contact dermatitis, milia, pain, discomfort, or a combination thereof.
7. The method of claim 2, wherein the symptom or side effect is a microbial infection.
8. The method of claim 1, wherein the length of the recovery phase is reduced to less than 7 days.
9. The method of any of the preceding claims, wherein the target skin is an integumental tissue selected from an epidermal, dermal, or hypodermal tissue.
10. The method of any of the preceding claims, wherein the target skin is on one or more of the face, forehead, eye region, cheek, nose, neck, scalp, head, shoulder, arm, hands, leg, underarm, torso, chest, feet, knee, ankle, calf, thigh, or buttocks of the subject.
11. The method of any of the preceding claims, wherein the preparation is administered less than 1 hour after the cosmetic procedure.
12. The method of claim 11, wherein a second or booster dose of the preparation is administered at least 6 hours after an initial administration of the preparation.
13. The method of any of the preceding claims, wherein the preparation is formulated for topical administration to the target skin.
14. The method of claim 13, wherein the preparation is formulated as an aqueous solution, gel, lotion, ointment, cream, serum, oil, salve, and / or solid.
15. The method of claim 13, wherein the preparation is formulated for administration by spray, aerosol, dropper, tube, ampule, or syringe.
16. The method of claim 13, wherein the preparation is formulated as a film, membrane, sheet, barrier dressing, or impregnated material.Docket No. G2093-7013WO17. The method of any of the preceding claims, wherein the preparation is formulated for parenteral administration to the target skin.
18. The method of any of the preceding claims, wherein the preparation consists of or consists essentially of the purified amphiphilic peptide in the aqueous biocompatible solution.
19. The method of any of the preceding claims, further comprising administering to the target skin a buffer configured to induce self-assembly of the peptide into the hydrogel, wherein the buffer comprises an effective amount of an ionic salt and a biological buffering agent.
20. The method of claim 19, comprising combining the preparation and the buffer prior to administration.
21. The method of claim 19, wherein the preparation and the buffer are administered separately.
22. The method of claim 19, wherein the buffer comprises between about 10 mM and 150 mM sodium chloride and between about 10 mM and 100 mM Bis-tris propane (BTP).
23. The method of any of the preceding claims, wherein the folding group comprises a turn sequence having 2-8 turn sequence amino acid residues selected to adopt a -turn.
24. The method of claim 23, wherein the turn sequence amino acid residues are independently selected from a D-proline, an L-proline, aspartic acid, threonine, asparagine, and combinations thereof.
25. The method of claim 24, wherein the turn sequence amino acid residues comprise a D-proline.
26. The method of claim 23, wherein the folding group comprises a first arm and a second arm flanking the turn sequence, each arm comprising alternating hydrophobic amino acid residues and charged amino acid residues.
27. The method of any of the preceding claims, wherein the folding group comprises 16-24 amino acid residues.Docket No. G2093-7013WO28. The method of any of the preceding claims, wherein:the hydrophobic amino acid residues are independently selected from glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, threonine, tryptophan, and combinations thereof; andthe charged amino acid residues are independently selected from arginine, lysine, histidine, and combinations thereof.
29. The method of claim 28, wherein the folding group has a sequence comprising Y[XY]N[T][XY]M, where X is 1-3 charged amino acids, Y is 1-3 hydrophobic amino acids, T is 0-8 turn sequence amino acids, and N and M are each independently between 2 and 10.
30. The method of claim 29, wherein X is selected from lysine and arginine, Y is valine, T is (d)PPT, and N and M are each 4.
31. The method of claim 30, wherein the peptide has a sequence of SEQ ID NO: 2.
32. The method of any of the preceding claims, wherein the peptide is at least 80% purified.
33. The method of any of the preceding claims, wherein the preparation is substantially free of a preservative.
34. The method of any of the preceding claims, wherein the preparation comprises between 0.01% w / v and 8.0% w / v of the peptide.
35. The method of claim 34, wherein the hydrogel comprises between 0.25% w / v and 6.0% w / v of the peptide.
36. The method of claim 35, wherein the hydrogel comprises between 0.1% w / v and 2.5% w / v of the peptide.
37. The method of any of the preceding claims, wherein the peptide has a net charge of from -10 to +11.Docket No. G2093-7013WO38. The method of claim 37, wherein the peptide has a net charge of from +5 to +9 at pH 7.4.
39. The method of any of the preceding claims, wherein the preparation and / or the hydrogel is sterilized.
40. The method of any of the preceding claims, wherein the peptide comprises acetate counterions.
41. The method of claim 40, wherein the peptide is free of chloride counterions.
42. The method of any of the preceding claims, wherein the peptide has a free amine at the N-terminus.
43. The method of any of the preceding claims, wherein the preparation is administered in combination with an anti-inflammatory agent, an ointment or moisturizer, a UV blocker, cold compress, analgesic or pain-relief composition, antibacterial composition, antifungal composition, antiviral composition, cell culture media, cell culture serum, a hemostatic composition, a biological material, or a combination thereof.
44. A method of facilitating regeneration of skin after a cosmetic procedure, comprising:providing a preparation comprising a purified amphiphilic peptide comprising a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern, the peptide being configured to self-assemble into a hydrogel; andproviding instructions to administer an effective amount of the preparation to a target skin of a subject that has received the cosmetic procedure.
45. The method of claim 44, further comprising providing a buffer configured to induce selfassembly of the peptide into the hydrogel.
46. The method of claim 45, wherein the preparation and the buffer are combined to form the hydrogel, and the method comprises providing instructions to administer an effective amount of the hydrogel to the target skin.Docket No. G2093-7013WO47. The method of any of claims 44-46, further comprising providing instructions to combine the preparation and a buffer configured to induce self-assembly of the peptide into the hydrogel prior to administration.
48. A preparation comprising:a purified amphiphilic peptide comprising a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern, the peptide being configured to self-assemble into a hydrogel;the preparation being formulated as a lotion, ointment, cream, serum, oil, or salve for topical application to skin.
49. A preparation comprising:a purified amphiphilic peptide comprising a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern, the peptide being configured to self-assemble into a hydrogel;the preparation being formulated as an impregnated material for topical application to skin.
50. The preparation of claim 49, wherein the impregnated material is a mask.
51. The preparation of claim 50, wherein the mask is a facial sheet mask, under eye mask or patch, spot patch or spot dot, forehead patch, chin patch, cheek patch, jawline or v-line lifting patch, nose patch or nose strip, neck mask, and / or chest mask.
52. The preparation of any of claims 48-51, wherein the folding group has a sequence comprising Y[XY]N[T][XY]M, where X is 1-3 charged amino acids, Y is 1-3 hydrophobic amino acids, T is 0-8 turn sequence amino acids, and N and M are each independently between 2 and 10.
53. The preparation of claim 52, wherein X is selected from lysine and arginine, Y is valine, T is (d)PPT, and N and M are each 4.
54. The preparation of claim 53, wherein the peptide has a sequence of SEQ ID NO: 2.Docket No. G2093-7013WO55. The preparation of any of claims 48-54, wherein the preparation is substantially free of a preservative.
56. The preparation of any of claims 48-55, wherein the preparation comprises between 0.01% w / v and 8.0% w / v of the peptide.
57. The preparation of claim 56, wherein the preparation comprises between 0.1% w / v and 2.5% w / v of the peptide.
58. The preparation of any of claims 48-57, wherein the peptide has a net charge of from -10 to +11.
59. The preparation of claim 58, wherein the peptide has a net charge of from +5 to +9 at pH 7.4.
60. The preparation of any of claims 48-59, wherein the peptide comprises acetate counterions.
61. The preparation of claim 60, wherein the peptide is free of chloride counterions.
62. The preparation of any of claims 48-61, wherein the peptide has a free amine at the N-terminus.
